{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "1oQggF7s7kOb",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d7edee27-e3da-4420-c6d5-cfa2eb527f59"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\r0% [Working]\r            \rGet:1 http://security.ubuntu.com/ubuntu jammy-security InRelease [110 kB]\n",
            "\r0% [Connecting to archive.ubuntu.com (91.189.91.82)] [1 InRelease 2,588 B/110 kB 2%] [Connected to c\r0% [Connecting to archive.ubuntu.com (91.189.91.82)] [Connected to cloud.r-project.org (18.239.18.39\r                                                                                                    \rGet:2 https://cloud.r-project.org/bin/linux/ubuntu jammy-cran40/ InRelease [3,626 B]\n",
            "\r                                                                                                    \r0% [Waiting for headers] [Waiting for headers] [Waiting for headers]\r                                                                    \rHit:3 https://ppa.launchpadcontent.net/c2d4u.team/c2d4u4.0+/ubuntu jammy InRelease\n",
            "\r0% [Waiting for headers] [Waiting for headers] [Waiting for headers]\r                                                                    \rGet:4 https://developer.download.nvidia.com/compute/cuda/repos/ubuntu2204/x86_64  InRelease [1,581 B]\n",
            "\r0% [Waiting for headers] [Waiting for headers] [4 InRelease 1,581 B/1,581 B 100%]\r                                                                                 \r0% [Waiting for headers] [Waiting for headers]\r                                              \rHit:5 https://ppa.launchpadcontent.net/deadsnakes/ppa/ubuntu jammy InRelease\n",
            "\r0% [Waiting for headers] [Waiting for headers]\r                                              \rHit:6 https://ppa.launchpadcontent.net/graphics-drivers/ppa/ubuntu jammy InRelease\n",
            "\r0% [Waiting for headers] [Waiting for headers]\r                                              \rHit:7 https://ppa.launchpadcontent.net/ubuntugis/ppa/ubuntu jammy InRelease\n",
            "Hit:8 http://archive.ubuntu.com/ubuntu jammy InRelease\n",
            "Get:9 http://archive.ubuntu.com/ubuntu jammy-updates InRelease [119 kB]\n",
            "Get:10 http://security.ubuntu.com/ubuntu jammy-security/universe amd64 Packages [1,077 kB]\n",
            "Get:11 http://security.ubuntu.com/ubuntu jammy-security/main amd64 Packages [1,702 kB]\n",
            "Hit:12 http://archive.ubuntu.com/ubuntu jammy-backports InRelease\n",
            "Get:13 http://security.ubuntu.com/ubuntu jammy-security/restricted amd64 Packages [2,148 kB]\n",
            "Get:14 https://developer.download.nvidia.com/compute/cuda/repos/ubuntu2204/x86_64  Packages [811 kB]\n",
            "Get:15 http://archive.ubuntu.com/ubuntu jammy-updates/universe amd64 Packages [1,369 kB]\n",
            "Get:16 http://archive.ubuntu.com/ubuntu jammy-updates/multiverse amd64 Packages [51.1 kB]\n",
            "Get:17 http://archive.ubuntu.com/ubuntu jammy-updates/main amd64 Packages [2,019 kB]\n",
            "Get:18 http://archive.ubuntu.com/ubuntu jammy-updates/restricted amd64 Packages [2,307 kB]\n",
            "Fetched 11.7 MB in 3s (4,006 kB/s)\n",
            "Reading package lists... Done\n",
            "drive  sample_data  spark-3.1.1-bin-hadoop3.2  spark-3.1.1-bin-hadoop3.2.tgz\n"
          ]
        }
      ],
      "source": [
        "!apt-get update # Update apt-get repository.\n",
        "!apt-get install openjdk-8-jdk-headless -qq > /dev/null # Install Java.\n",
        "!wget -q http://archive.apache.org/dist/spark/spark-3.1.1/spark-3.1.1-bin-hadoop3.2.tgz # Download Apache Sparks.\n",
        "!tar xf spark-3.1.1-bin-hadoop3.2.tgz # Unzip the tgz file.\n",
        "!pip install -q findspark # Install findspark. Adds PySpark to the System path during runtime.\n",
        "\n",
        "# Set environment variables\n",
        "import os\n",
        "os.environ[\"JAVA_HOME\"] = \"/usr/lib/jvm/java-8-openjdk-amd64\"\n",
        "os.environ[\"SPARK_HOME\"] = \"/content/spark-3.1.1-bin-hadoop3.2\"\n",
        "\n",
        "!ls\n",
        "\n",
        "# Initialize findspark\n",
        "import findspark\n",
        "findspark.init()"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from pyspark import SparkConf, SparkContext\n",
        "from pyspark.sql import SparkSession"
      ],
      "metadata": {
        "id": "B22dINvn8x3g"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a SparkContext\n",
        "conf = SparkConf().setMaster(\"local\").setAppName(\"KMeansPatientCharacteristics\") # treat every core of your desktop as an executor\n",
        "SpContext = SparkContext(conf = conf)"
      ],
      "metadata": {
        "id": "VwAKsf0O8zpX"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "SpSession = SparkSession.builder.config(\"spark.sql.warehouse.dir\", \"file:///C:/temp\").getOrCreate()"
      ],
      "metadata": {
        "id": "Sc-OD8gu81jG"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Load the CSV file into a RDD\n",
        "patientData = SpContext.textFile(\"/content/drive/MyDrive/hca_datasets/11-patient-characteristics-cluster.csv\",2)\n",
        "patientData.cache()\n",
        "patientData.collect()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yehKvDM98343",
        "outputId": "a47c9216-76bb-43c1-ef3f-3573761390d4"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['Excluded: Patients whose use of alcohol or drugs is sufficient to impair compliance with protocol requirements.',\n",
              " 'Current substance or alcohol use disorder as determined by the SCID or by positive drug toxicology results',\n",
              " 'Subjects who consume >14 alcoholic drinks per week.',\n",
              " 'Excessive consumption of xanthine-based beverages',\n",
              " 'History of drug abuse or use of illegal drugs: use of soft drugs (marijuana  pot) within 3 months of the screening visit or hard drugs (cocaine  PCP  crack)within 1 year of the screening visit',\n",
              " 'Non-smokers.',\n",
              " 'Smokers may participate  but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules',\n",
              " 'Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [ 1 Unit = 150mL of wine  360 mL of beer  or 45mL of 40% alcohol])',\n",
              " 'Use of soft drugs ( such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine  phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug at screening.',\n",
              " 'Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months',\n",
              " 'subjects who have discontinued smoking or the use of nicotine/nicotine containing products for at least approximately 3 months may be enrolled in the study at the discretion of the investigator',\n",
              " 'Current use of tobacco products including cigarettes  cigars  pipes  or chewing tobacco  current participation in a smoking cessation program  or discontinuation of smoking within 3 months prior to screening',\n",
              " 'Exclusion Criteria: Consumption greater than 14 alcoholic drinks per week',\n",
              " 'alcoholism  drug addiction  acute withdrawal from chemical dependency  psychiatric disease)',\n",
              " 'Be current smokers of cigarettes (past 7 days)',\n",
              " 'History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week',\n",
              " 'History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day',\n",
              " 'Inebriated',\n",
              " 'or abstinence',\n",
              " 'Patients who are currently cigarette smokers.',\n",
              " 'Smokes at least 20 cigarettes per day (1 pack per day)',\n",
              " 'Smoking',\n",
              " 'Smoking  alcohol intake (more than 2 drinks/week)',\n",
              " 'Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help them quit smoking',\n",
              " 'Subjects who are  appear to be  or are known  current or former drug addicts or alcoholics.',\n",
              " 'History of drug abuse during prior twelve months',\n",
              " 'History of smoking  alcoholism  and use of illicit drugs',\n",
              " 'Patient has a history of substance abuse within the past year.',\n",
              " 'Have been a smoker in the past 12 months',\n",
              " 'Have smoked an average of at least 10 cigarettes/day in the preceding year  with < 3 month total abstinence period',\n",
              " 'Subject is a nonsmoker or has not used nicotine-containing products for 6 months prior to study start',\n",
              " 'Existing Substance abuse',\n",
              " 'Use of any tobacco products in the 6 months proceeding drug administration.',\n",
              " 'Abuse alcohol or drugs.',\n",
              " 'Abuse alcohol or require drugs which  in the opinion of the investigator  may increase the risk of pancreatitis.',\n",
              " 'Abuse drugs or alcohol.',\n",
              " 'abusive drug or alcohol consumption.',\n",
              " 'alcohol high consumption',\n",
              " 'Alcohol or drug abuse',\n",
              " 'Are known to have had a substance abuse (drug or alcohol) problem within the previous 3 years',\n",
              " 'Self-reported level of motivation to stop smoking >=  7  on a scale of 1-to-10',\n",
              " 'Subjects who consume > 14 alcoholic drinks per week',\n",
              " 'Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.',\n",
              " 'has a history of alcohol or drug abuse within the past year',\n",
              " 'Have had at least one HIV risk behavior (unprotected sexual activity  sharing injection drug needles without following CDC guidelines for needle-cleaning  sexual activity while under the influence of drugs or alcohol) during the three-month period prior t',\n",
              " 'History of alcoholism or drug abuse within 12 months of the study.',\n",
              " 'History of significant alcohol abuse or drug abuse within one year prior to the screening visit.',\n",
              " 'Patients with excessive alcohol consumption or alcoholism that would be contraindicated with the use of acetaminophen.',\n",
              " 'Subjects who have a history of alcohol or drug abuse within 1 year of study entry',\n",
              " 'The presence of alcoholism or drug abuse within the past year',\n",
              " 'history of smoking within 2 years of surgery  or',\n",
              " 'alcohol consumption > 14 drinks per week',\n",
              " 'Exclusion Criteria: Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month',\n",
              " 'Chronic alcohol or illicit drug use',\n",
              " 'Drug or alcohol abuse within 12 months of enrollment.',\n",
              " 'had a history of alcohol or substance abuse within 12 months of enrolment',\n",
              " 'History of drug or alcohol abuse or dependence',\n",
              " 'Ingestion of alcohol within 1 week of the first dose of study medication.',\n",
              " 'Recent history of drug and/or alcohol abuse',\n",
              " 'Recent history of drug or alcohol abuse.',\n",
              " 'Subject consumes more than 3 alcoholic beverages per day',\n",
              " 'Subject consumes more than 6 caffeinated beverages per day',\n",
              " 'Active substance abuse or dependence',\n",
              " 'Active substance abuse or illegal drug use.',\n",
              " 'Active substance abuse.',\n",
              " 'Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine)',\n",
              " 'Substance abuse',\n",
              " 'Substance abuse or dependence within the past 3 months  except for nicotine',\n",
              " 'Have a history of drug abuse in the past 2 years and/or positive finding on urinary drug screening  other than prescribed medication.',\n",
              " 'History of drug abuse or use of illegal drugs: soft drugs (marijuana) within 3 months prior to the screening visit or hard drugs (cocaine  PCP  crack) within 1 year prior to the screening visit or positive urine drug screen at screening',\n",
              " 'Recent history of drug abuse or use of illegal drugs: soft drugs (marijuana  pot) use within 3 months of the screening visit and hard drugs (cocaine  PCP  crack) use within 1 year of the screening visit',\n",
              " 'Residing in Bandiagara for the duration of the study',\n",
              " 'Residence in skilled nursing facility',\n",
              " 'Subjects living too far from participating center or unable to return for follow-up visits',\n",
              " 'All patients presenting to Mayo Clinic  Jacksonville  Florida for a screening  surveillance colonoscopy  and/or a diagnostic and surveillance upper endoscopy  will be eligible based on inclusion and exclusion criteria',\n",
              " 'Live within 10 miles of UCLA',\n",
              " 'Patient who live and can be located in the Kintampo District.',\n",
              " 'Reside within zip codes corresponding to the lowest performing schools in the broad Miami area',\n",
              " 'Residing in Lambarene for the duration of the study',\n",
              " 'Living in an area where Arthritis Foundation aquatic programs were offered',\n",
              " 'A rural population in the middle belt of Ghana',\n",
              " 'Eligible patients will be offered entry into the study on the day of the procedure in the hospital GI or Mayo Clinic Jacksonville endoscopy suites.',\n",
              " \"Inclusion Criteria: Inborn at Brigham and Women's Hospital  Boston\",\n",
              " 'Inclusion Criteria: Healthy men or women 18 years of age or older',\n",
              " 'Inclusion Criteria: Male & Females aged 65 and older',\n",
              " 'Inclusion Criteria: Male and female outpatients 18 years of age or older.',\n",
              " 'Inclusion criteria: Male and female patients aged above ten years.',\n",
              " 'Inclusion Criteria: Male and female subjects must be at least 45 years old at the time of consent.',\n",
              " 'Inclusion Criteria: Male or female 12-70 years of age (inclusive).',\n",
              " 'Inclusion Criteria: Men and women >= 18 years of age',\n",
              " 'Inclusion Criteria: Men or women aged 60-85  inclusive',\n",
              " 'Key Inclusion Criteria: Female and male subjects must be 18 to 65 years of age',\n",
              " 'Men or women ages greater than or equal to 55 years',\n",
              " 'Inclusion Criteria: all patients above 18 years',\n",
              " 'Inclusion Criteria: Male or female subjects 18 to 65 years inclusive.',\n",
              " 'Age group 6-25 years.',\n",
              " 'Inclusion Criteria: 18 and 45 years',\n",
              " 'Must be 18 or over',\n",
              " 'Any subject over 18 years of age ',\n",
              " '18- 45 years old',\n",
              " '18 years of age and older',\n",
              " '18 years of age or older',\n",
              " '18 years of age.',\n",
              " '18 years or older',\n",
              " '18-80 years of age',\n",
              " 'Patients must be in the age range of 40 to 80 years.',\n",
              " 'age < 18 years',\n",
              " 'age < 21',\n",
              " 'Age <18 years or >80 years',\n",
              " 'age = or > than 70 years',\n",
              " 'Age > 18 years',\n",
              " 'Age > 18 years.',\n",
              " 'Age > 60 years',\n",
              " 'Age >18years',\n",
              " 'Age >4.0 to <10.0 years',\n",
              " 'Age >= 18 years',\n",
              " 'Age  >= 6 years.',\n",
              " 'Age 18 - 80 Years',\n",
              " 'age 18 to 65 years',\n",
              " 'age 18-65 years',\n",
              " 'Age 21 to 60 years (inclusive).',\n",
              " 'Age  >= 18 years.',\n",
              " 'Age between 35 and 75 years.',\n",
              " 'Age less than 18',\n",
              " 'Age limits (see below)',\n",
              " 'Age of at least 18 years and 75 years or less',\n",
              " 'Age older then 18 years of age.',\n",
              " 'Age over 18 years',\n",
              " 'Age over 50 years',\n",
              " 'Aged 55 to 75',\n",
              " 'Ages 18 - 60 years old',\n",
              " 'Ages 18-80',\n",
              " 'Ages Eligible for Study: 1 Month to 18 Years',\n",
              " 'Ages Eligible for Study: 1 Year and older',\n",
              " 'Ages Eligible for Study: 1 Year to 18 Years',\n",
              " 'Ages Eligible for Study: 10 Years and older',\n",
              " 'Ages Eligible for Study: 11 Months to 14 Months',\n",
              " 'Ages Eligible for Study: 11 Years to 16 Years',\n",
              " 'Ages Eligible for Study: 11 Years to 18 Years',\n",
              " 'Ages Eligible for Study: 12 Years and older',\n",
              " 'Ages Eligible for Study: 12 Years to 70 Years',\n",
              " 'Ages Eligible for Study: 13 Years and older',\n",
              " 'Ages Eligible for Study: 13 Years to 17 Years',\n",
              " 'Ages Eligible for Study: 13 Years to 18 Years',\n",
              " 'Ages Eligible for Study: 15 Years to 18 Years',\n",
              " 'Ages Eligible for Study: 15 Years to 45 Years',\n",
              " 'Ages Eligible for Study: 16 Years and older',\n",
              " 'Ages Eligible for Study: 16 Years to 70 Years',\n",
              " 'Ages Eligible for Study: 18 Years and older',\n",
              " 'Ages Eligible for Study: 18 Years to 24 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 25 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 26 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 35 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 40 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 45 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 50 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 55 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 60 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 65 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 70 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 75 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 76 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 80 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 85 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 90 Years',\n",
              " 'Ages Eligible for Study: 18 Years to 95 Years',\n",
              " 'Ages Eligible for Study: 19 Years and older',\n",
              " 'Ages Eligible for Study: 19 Years to 39 Years',\n",
              " 'Ages Eligible for Study: 19 Years to 50 Years',\n",
              " 'Ages Eligible for Study: 19 Years to 90 Years',\n",
              " 'Ages Eligible for Study: 2 Years to 10 Years',\n",
              " 'Ages Eligible for Study: 20 Years and older',\n",
              " 'Ages Eligible for Study: 20 Years to 30 Years',\n",
              " 'Ages Eligible for Study: 20 Years to 60 Years',\n",
              " 'Ages Eligible for Study: 20 Years to 64 Years',\n",
              " 'Ages Eligible for Study: 20 Years to 80 Years',\n",
              " 'Ages Eligible for Study: 21 Years and older',\n",
              " 'Ages Eligible for Study: 21 Years to 50 Years',\n",
              " 'Ages Eligible for Study: 21 Years to 60 Years',\n",
              " 'Ages Eligible for Study: 21 Years to 75 Years',\n",
              " 'Ages Eligible for Study: 21 Years to 89 Years',\n",
              " 'Ages Eligible for Study: 25 Years to 65 Years',\n",
              " 'Ages Eligible for Study: 28 Weeks to 33 Weeks',\n",
              " 'Ages Eligible for Study: 3 Months to 12 Years',\n",
              " 'Ages Eligible for Study: 3 Months to 18 Years',\n",
              " 'Ages Eligible for Study: 3 Years and older',\n",
              " 'Ages Eligible for Study: 30 Years and older',\n",
              " 'Ages Eligible for Study: 30 Years to 70 Years',\n",
              " 'Ages Eligible for Study: 35 Years to 75 Years',\n",
              " 'Ages Eligible for Study: 4 Years to 9 Years',\n",
              " 'Ages Eligible for Study: 40 Years and older',\n",
              " 'Ages Eligible for Study: 40 Years to 80 Years',\n",
              " 'Ages Eligible for Study: 45 Years and older',\n",
              " 'Ages Eligible for Study: 45 Years to 60 Years',\n",
              " 'Ages Eligible for Study: 5 Years to 65 Years',\n",
              " 'Ages Eligible for Study: 50 Years and older',\n",
              " 'Ages Eligible for Study: 50 Years to 80 Years',\n",
              " 'Ages Eligible for Study: 55 Years and older',\n",
              " 'Ages Eligible for Study: 55 Years to 75 Years',\n",
              " 'Ages Eligible for Study: 55 Years to 85 Years',\n",
              " 'Ages Eligible for Study: 6 Weeks to 14 Weeks',\n",
              " 'Ages Eligible for Study: 6 Years to 13 Years',\n",
              " 'Ages Eligible for Study: 6 Years to 18 Years',\n",
              " 'Ages Eligible for Study: 6 Years to 20 Years',\n",
              " 'Ages Eligible for Study: 6 Years to 25 Years',\n",
              " 'Ages Eligible for Study: 60 Years and older',\n",
              " 'Ages Eligible for Study: 60 Years to 80 Years',\n",
              " 'Ages Eligible for Study: 60 Years to 85 Years',\n",
              " 'Ages Eligible for Study: 60 Years to 89 Years',\n",
              " 'Ages Eligible for Study: 65 Years and older',\n",
              " 'Ages Eligible for Study: 75 Years and older',\n",
              " 'Ages Eligible for Study: 9 Years to 15 Years',\n",
              " 'Ages Eligible for Study: up to 21 Years',\n",
              " 'Ages Eligible for Study: up to 24 Hours',\n",
              " 'Ages Eligible for Study: up to 3 Months',\n",
              " 'Ages Eligible for Study: up to 3 Years',\n",
              " 'Ages Eligible for Study: up to 59 Months',\n",
              " 'Ages Eligible for Study: up to 6 Years',\n",
              " 'All patients must be aged 18 years and older.',\n",
              " 'Are at least 13 years old ',\n",
              " 'Are at least 16 years old ',\n",
              " 'Are between the ages of 18 and 70 years of age  inclusive.',\n",
              " 'Be 18 years of age or older.',\n",
              " 'Be 18 years old or older.',\n",
              " 'Be a male or female at least 18 years of age ',\n",
              " 'Be at least 18 years of age',\n",
              " 'Be between the ages of 18 and 45 years old  inclusive',\n",
              " 'Between 18 and 55 years of age',\n",
              " 'Boys and girls between the ages of 9-15.',\n",
              " 'Children ten years and below (to be catered for in the child antimalarial efficacy studies mentioned above).',\n",
              " 'Criteria for children 15 months to 12 years of age',\n",
              " 'Exclusion Criteria: < 18 years of age',\n",
              " 'Exclusion Criteria: Age <21 years*',\n",
              " 'Exclusion Criteria: age > 75 years',\n",
              " 'Exclusion Criteria: Age less than 18 years',\n",
              " 'Exclusion Criteria: Individuals younger than 11 years and older than 18 years',\n",
              " 'Exclusion Criteria: Patient is less than 18 years of age',\n",
              " 'Exclusion Criteria: Patient less than 18 years of age',\n",
              " 'For all: Age 15-18',\n",
              " 'In addition  they must meet all of the following criteria: be at least 18 years of age',\n",
              " 'Inclusion Criteria: 10 years or older',\n",
              " 'Inclusion Criteria: 18 to 85 years of age',\n",
              " 'Inclusion Criteria: 18 years of age and older',\n",
              " 'Inclusion Criteria: 18 years to 75 years of age',\n",
              " 'Inclusion Criteria: 18-65 years of age',\n",
              " 'Inclusion Criteria: age <= 75 years',\n",
              " 'Inclusion Criteria: Age > 1 year',\n",
              " 'Inclusion Criteria: Age > 18',\n",
              " 'Inclusion Criteria: age > 18 years',\n",
              " 'Inclusion Criteria: Age > 60 years',\n",
              " 'Inclusion Criteria: Age >= 18 years',\n",
              " 'Inclusion Criteria: Age 1 to 5 years old',\n",
              " 'Inclusion Criteria: Age 18-45 years',\n",
              " 'Inclusion Criteria: Age 18-55 years inclusive at the time of screening',\n",
              " 'Inclusion Criteria: Age 19 and older',\n",
              " 'Inclusion Criteria: Age 21-89',\n",
              " 'Inclusion Criteria: Age 40 to 80 years  inclusive.',\n",
              " 'Inclusion Criteria: Age greater than 18',\n",
              " 'Inclusion Criteria: Age greater than 18 and less than 90',\n",
              " 'Inclusion Criteria: Age is 18 and older.',\n",
              " 'Inclusion Criteria: Age over 18 years',\n",
              " 'Inclusion Criteria: Age: 18-80 ',\n",
              " 'Inclusion Criteria: aged 65 years or older',\n",
              " 'Inclusion Criteria: Ages 18 to 100',\n",
              " 'Inclusion Criteria: Are aged 55-85 years  inclusive',\n",
              " 'Inclusion Criteria: Boys and girls ages 9-15',\n",
              " 'Inclusion Criteria: Children between 6 and 18 years',\n",
              " 'Inclusion Criteria: Must be between 21 and 50 years of age',\n",
              " 'Inclusion Criteria: patients >18 years old',\n",
              " 'Inclusion Criteria: patients aged 75 years old or more',\n",
              " 'Inclusion Criteria: Subject is between 18 and 55 years of age',\n",
              " 'Patient greater than or equal to 18 years of age',\n",
              " 'Patient must be > 18 years of age.',\n",
              " 'Patients must be >=  18 years of age.',\n",
              " 'Patients must be older than one year of age',\n",
              " 'Patients who are younger than 18 years of age',\n",
              " 'Subject is >=  18 years old.',\n",
              " 'Subject may be of any age',\n",
              " 'Subjects must be >= 18 years and <= 75 years of age.',\n",
              " 'Subjects must be >=18 years and <=75 years of age.',\n",
              " 'Subjects up to 65 years of age may be enrolled in Panels B and C',\n",
              " 'Under 18 years of age',\n",
              " 'Under the age of 19',\n",
              " 'Exclusion Criteria: Under 18',\n",
              " 'Had a history or presence of dermal hypersensitivity',\n",
              " 'A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to Exelon or to other cholinergic compounds  .  pilocarpine  bethanechol  tacrine  velnacrine  donepezil  metrifonate  or physostigmine)',\n",
              " 'Exclusion Criteria: Hypersensitivity to the active ingredient or one of the components of the drug',\n",
              " 'Exclusion Criteria: Sensitivity to immune globulin preparations or any benzodiazepine',\n",
              " 'History of hypersensitivity or intolerability to either desloratadine or fexofenadine or other antihistamines.',\n",
              " 'history of hypersensitivity to active or inactive excipients of tamoxifen and Zoladex',\n",
              " 'History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)',\n",
              " 'History of hypersensitivity to the investigational products or to drugs with similar chemical structures',\n",
              " 'History of hypersensitivity to zolpidem  eszopiclone  or flurazepam.',\n",
              " 'Hypersensitivity or idiosyncratic reaction to buspirone HCl',\n",
              " 'Hypersensitivity to any component of ZYFLO CR',\n",
              " 'Hypersensitivity to didanosine (ddI).',\n",
              " 'Hypersensitivity to Irbesartan.',\n",
              " 'Hypersensitivity towards any component of degarelix or mannitol',\n",
              " 'hypersensitivity or idiosyncratic reaction to buspirone HCl.',\n",
              " 'Known history of sensitivity to cyclogyl and/or proparacaine HCL 0.5%',\n",
              " 'Known hypersensitivity to alfuzosin',\n",
              " 'Known hypersensitivity to any study drug component.',\n",
              " 'Known hypersensitivity to Argatroban or related compounds.',\n",
              " 'Known hypersensitivity to AZT.',\n",
              " 'Known hypersensitivity to estrogens  progestins  or other ingredients of Totelle',\n",
              " 'Known hypersensitivity to IV or oral ganciclovir.',\n",
              " 'Known hypersensitivity to murine or chimeric antibodies.',\n",
              " 'Known hypersensitivity to the study drugs.',\n",
              " 'No hypersensitivity to trastuzumab (Herceptin??)',\n",
              " 'Patient has hypersensitivity to gabapentin.',\n",
              " 'Patients who are sensitive or allergic to aspirin.',\n",
              " 'Patients with the following are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.',\n",
              " 'Polyene hypersensitivity ',\n",
              " 'Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.',\n",
              " 'Patients with the following conditions or symptoms are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.',\n",
              " 'Intolerance to Losartan therapy',\n",
              " 'Allergic to insulin',\n",
              " 'Allergy against niacin oder other ingredient of niaspan',\n",
              " 'Allergy to DHA (Omega 3) or Vitamin D',\n",
              " 'Allergy to fluorescein',\n",
              " 'Allergy to lactose.',\n",
              " 'Allergy to trial required medications',\n",
              " 'Are allergic to study drugs or any ingredient in them.',\n",
              " 'Exclusion Criteria: allergy to dairy proteins',\n",
              " 'Food allergies to the study food',\n",
              " 'Have an allergy to soybean oil and/or eggs',\n",
              " 'History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.',\n",
              " 'History of allergic reactions or anaphylaxis to immunizations or to any vaccine component',\n",
              " 'History of allergic reactions to cabergoline or ergot derivatives',\n",
              " 'History of allergic reactions to heparin',\n",
              " 'History of allergic reactions to heparin  doxycycline  or other related drugs',\n",
              " 'History of allergic reactions to heparin  propranolol  or other related drugs.',\n",
              " 'history of allergies to lidocaine',\n",
              " 'History of allergy to any of the proposed treatment or its alternatives  i.e',\n",
              " 'History of allergy to vaccines components',\n",
              " 'History of drug allergy of clinical significance in the opinion of the investigator.',\n",
              " 'History of serious allergic reaction to any substance  requiring hospitalization or emergent medical care  ',\n",
              " 'History of serious allergic reactions to any substance  requiring hospitalization or emergent medical care',\n",
              " 'History of serious allergic reactions to any substance  requiring hospitalization or emergent medical care or history of allergy to vaccines components',\n",
              " 'Known allergies to aspirin  clopidogrel bisulphate (Plavix??) and ticlopidine (Ticlid??)  heparin  or stainless steel',\n",
              " 'Known allergies to the same class of drug and/or allergies to eggs',\n",
              " 'Known allergy to tetracycline.',\n",
              " 'No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug',\n",
              " 'Patient with known allergy to iodine  iodine containing drugs or contrast agent',\n",
              " 'Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib  boron or mannitol.',\n",
              " 'Patients with a history of allergic reaction to an intra-articular injection or avian products.',\n",
              " 'Patients with known allergies to acetaminophen  lidocaine  hyaluronans  or avian products.',\n",
              " 'Reported allergy to egg proteins  chicken proteins or any other constituent of the vaccine.',\n",
              " 'Subject has a documented allergy to radiographic contrast that cannot be pre-treated.',\n",
              " 'Subject has a documented allergy to the device materials.',\n",
              " 'Subject has multiple and/or severe allergies to drugs or food',\n",
              " 'Subjects who have a clinically significant history of food or drug allergy.',\n",
              " 'You are allergic to amitriptyline or duloxetine.',\n",
              " 'Known previous intolerance to zidovudine (AZT) at 500 mg/day.',\n",
              " 'Subject has documented intolerance to BOTH heparin and Angiomax.',\n",
              " 'History of grade 3 or worse intolerance to 500-600 mg/day AZT.',\n",
              " 'Known intolerance or inefficacy to either drug.',\n",
              " 'Usual bedtime between 21:00 and 01:00',\n",
              " 'habitual bedtime between 9:00 pm and 1:00 am. ',\n",
              " 'reports habitual bedtime earlier than 9 pm or later than 1 am > 2 times per week ',\n",
              " 'regular sleep habits  including bedtime between 9 pm and midnight. ',\n",
              " 'self-report bedtimes that do not vary by > two hours on five nights per week ',\n",
              " 'sleep onset latency and / or bedtime resistance ',\n",
              " 'over the last three months for >= 5 nights per week  must have a normal bedtime of between 9 pm and 1 am and a time in bed of >= 7 hours ',\n",
              " \"patient's bedtime is between 9 pm and 1 am \",\n",
              " 'habitual bedtime should be determined by sleep history as between 9:00 pm and 12:00 am as determined by sleep history prior to randomization',\n",
              " 'have regular bedtime (within 1 hour) for 1 week prior to travel. ',\n",
              " 'usual bedtimes between 9:00 pm and midnight. ',\n",
              " 'patients who experience rls symptoms requiring treatment after 17:00 but prior to bedtime.',\n",
              " 'the subject has a history of the following sleep characteristics during the past three months or more at visit 1: bedtime between 22:00-00:00 h on >= five nights per week ',\n",
              " 'the patient has a habitual bedtime between 2100 and 2400. ',\n",
              " \"patient's usual bedtime is between 9 p. m \",\n",
              " 'their sleep schedule will include a typical bedtime of between 9:00 p. m',\n",
              " 'Anticipated availability for blood draw 4-6 weeks following 3rd vaccine dose',\n",
              " 'Ability to tolerate oral therapy.',\n",
              " 'Are unable to take medications by mouth.',\n",
              " \"Recent evidence of or history of significant psychiatric illness that may have compromised the subject's ability to comply with the study requirements\",\n",
              " 'Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.',\n",
              " 'Inability to communicate or cooperate with the investigator because of a language problem  poor mental status  or impaired cerebral status.',\n",
              " 'Available for the duration of the study.',\n",
              " 'Available to participate in follow-up for the duration of study (13 months)',\n",
              " 'Available to start intervention within 6 weeks',\n",
              " 'Available for 12 months of follow-up and able to complete study assessments as per clinician judgment',\n",
              " 'Parent/legal representative able to attend all scheduled visits and comply with all trial procedures.',\n",
              " 'Subject is unable to refrain from or anticipates the use of any medication (with the exception of metformin or sulfonylurea agents)  including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks until the post-study v',\n",
              " 'Are available for at least 8 weeks.',\n",
              " 'Must be able to adhere to the study visit schedule and other protocol requirements',\n",
              " 'Patients who are able to tolerate ICD programming as specifically prescribed in the study protocol',\n",
              " 'Clinically significant disorder including excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator',\n",
              " 'Mental incapacity or language barrier precluding adequate understanding or cooperation',\n",
              " 'Adequate vision and hearing to participate in study assessments.',\n",
              " 'Can communicate verbally or with assistive device',\n",
              " 'Available to participate in follow-up for the duration of study (14 months)',\n",
              " 'Any reason which  in the opinion of the medical subinvestigator  would prevent the subject from participating in the study',\n",
              " 'Exclusion Criteria: can not answer a written questionaire',\n",
              " 'Patients who are unable to complete quality of life questionnaires',\n",
              " 'Patients who can perform the 50-foot walk test without the support of crutches or other assistive devices  except for canes',\n",
              " 'Patients who cannot perform the 50-foot walk test without the support of crutches or other assistive devices  except for canes',\n",
              " 'Able to follow 3-stage commands',\n",
              " 'Able to recall 2/3 objects after 30 minutes',\n",
              " 'Can swallow capsules',\n",
              " 'Difficulty to swallow study medication.',\n",
              " 'Patients will be excluded from this study for the following reasons: If they are unable to walk several blocks for whatever reason',\n",
              " 'Capable of completing a 3-day food intake diary with instruction',\n",
              " 'Difficulty to swallow study medication',\n",
              " 'Must be able to swallow pills',\n",
              " 'Able to understand the nature of the study and what will be required of them.',\n",
              " 'Ability to walk 30 feet without assistance (cane and leg bracing is permitted).',\n",
              " 'Exclusion Criteria: Patient not being able to walk',\n",
              " 'Subjects must understand the dosing schedule.',\n",
              " 'Able to perform 6 minute hall walk',\n",
              " 'Able to self-administer study medication by subcutaneous injection or caregiver available to administer study medication.',\n",
              " 'Able to take oral medications',\n",
              " 'Exclusion Criteria: Patients who are unable to walk several blocks regardless of the reason will be excluded from all the trials  .  arthritis  stroke  claudication).',\n",
              " 'Patients unable to or with any psychiatric illness that would prevent them to legally comprehend the details and nature of the study.',\n",
              " 'Caregiver available to assist with the device every day (unless subject capable of using it independently',\n",
              " 'Diaphragmatic weakness such that patients are unable to tolerate supine position  or swallowing impairment such that patients are unable to maintain nutrition without use of gastrostomy.',\n",
              " 'Subject is unable to respond to external questions and stimuli and to exert a pressure with the contralateral hand.',\n",
              " \"The participant must also be able to correctly rank the following three levels of pain from highest to lowest: 1) falling from a 2-story building and breaking both ankles  2) stubbing one's toe and 3) getting bitten by a mosquito.\",\n",
              " 'Unable to take oral medication reliably.',\n",
              " 'Patient or family inability to understand or cooperate with study procedures',\n",
              " 'Patient must be able to attend all required follow-up visits at the study center.',\n",
              " \"You must be able to visit the doctor's office once a week for ten (10) weeks.\",\n",
              " 'Exclusion Criteria: Patients who are unable to walk several blocks for any reason.',\n",
              " 'patients who  for whatever reason(eg  confusion  infirmity alcoholism) are unlikely to comply with trial requirements',\n",
              " 'Ability to comply with the requirements of the entire study',\n",
              " 'Intellectual  emotional  and physical ability to comply with oral medication.',\n",
              " 'Capability of complying with study protocol.',\n",
              " 'Patient must be able to comply with treatment regimen.',\n",
              " 'Patients must be able to comply and understand the use of a diary',\n",
              " 'Be able to comply with all study procedures',\n",
              " 'Able to comply with all required study procedures and schedule',\n",
              " 'The subject  in the opinion of the principal investigator  is unlikely to comply with the study protocol or is unsuitable for any other reason.',\n",
              " 'Unlikely to comply with follow-up protocol',\n",
              " 'Unlikely to comply with the study protocol and prescribed treatment or is unsuitable for any other reason in the opinion of the investigator',\n",
              " 'Patient must complete the pre-treatment quality of life questionnaires.',\n",
              " 'Will not engage in direct patient care until immunization scab falls off (around 21 days or 3 weeks after vaccination) if health care worker',\n",
              " 'Subject cannot stop taking any of their current prescription or non-prescription medications during the study',\n",
              " 'Inclusion Criteria: Adherence to prior or current HAART was or is being compromised  or HAART was discontinued/interrupted due to nausea/vomiting',\n",
              " 'Inability to comply with study and follow-up procedures.',\n",
              " 'Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol',\n",
              " 'No serious medical or psychiatric illness preventing informed consent or intensive treatment  ',\n",
              " 'Ability to provide written informed consent and/or assent.',\n",
              " 'Ability to voluntarily provide written informed consent prior to treatment.',\n",
              " 'Able to provide consent',\n",
              " 'Be able to give informed consent.',\n",
              " 'Be capable of reading and understanding patient information materials and giving written informed consent.',\n",
              " 'Capable of consent',\n",
              " 'Exclusion Criteria: Inability to give written informed consent.',\n",
              " 'Exclusion Criteria: Inability to provide informed consent',\n",
              " 'If they are unable to provide informed consent because of cognitive deficits',\n",
              " 'Inability to provide consent',\n",
              " 'Patient must be able to provide informed consent.',\n",
              " 'Patients must be able to provide informed consent',\n",
              " 'Patients must be able to provide informed consent within the one week after the procedure.',\n",
              " 'Patients who are able to give informed consent',\n",
              " 'Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study',\n",
              " 'Patients who are unable to provide consent.',\n",
              " 'Patients who are unable to provide informed consent.',\n",
              " 'Unable to provide consent',\n",
              " 'Women able to consent for themselves',\n",
              " 'Women unable to consent for themselves',\n",
              " 'Exclusion Criteria: Failure to provide an informed consent',\n",
              " 'Informed consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the procedure to be followed  the experimental nature of the therapy  alternatives  potential benefits',\n",
              " 'Parent or guardian willing to provide informed consent',\n",
              " 'Parental non-consent',\n",
              " 'Patient or guardian available to give written informed consent.',\n",
              " 'Patients must have the following: Parent or guardian available to give written informed consent.',\n",
              " 'Patients must sign study-specific informed consent prior to study entry.',\n",
              " 'Unable to obtain or refusal to consent prior to surgery',\n",
              " '(2) Ability and willingness to provide signed  witnessed informed consent.',\n",
              " 'Any reason which  in the opinion of the Medical Sub- Investigator  would prevent the subject from participating in the study.',\n",
              " 'Patients who in the judgment of the clinician are likely to violate the protocol regulations or unlikely to complete the study for any reason.',\n",
              " 'If under legal age  must have legal guardian who is able to give consent',\n",
              " 'Exclusion Criteria: unable to provide informed consent',\n",
              " 'Inability to provide informed consent signed.',\n",
              " 'Inability to provide informed consent.',\n",
              " 'Must be able to give written informed consent',\n",
              " 'Persons lacking consent capacity',\n",
              " 'Consent of parent or guardian if less than 18 years of age.',\n",
              " 'Consent of patient and parent or guardian if less than 18 years of age.',\n",
              " 'An informed consent obtained from the patient or his/her guardian and assent for children',\n",
              " 'Consent of patient and/or care giver (in the case of children)',\n",
              " 'Subject (or legal representative) understands the nature of the procedure and provides informed consent  prior to enrollment in the study.',\n",
              " 'Evidence of signed and dated informed consent document (by the patient or a legal guardian) indicating that the patient and/or the legal guardian has been informed of all pertinent aspects of the trial.',\n",
              " 'Meets the eligibility requirements for registration  .  within certain time windows from annual visits  having signed informed consent for Respiratory Ancillary Study [RAS]  at a site which has concurrent Institutional Review Board [IRB] approval for RAS)',\n",
              " 'Signed ICF',\n",
              " 'Signed  informed parental consent if patient is less than 18.',\n",
              " 'Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood-sampling visit of each year',\n",
              " 'Absence of informed consent ',\n",
              " 'All patients must have given signed  informed consent prior to registration to the study.',\n",
              " 'Confirmed written informed consent',\n",
              " 'Consent not signed',\n",
              " 'Consent obtained before first dose of PCV-7 is given',\n",
              " 'Exclusion Criteria: Informed consent not obtained',\n",
              " 'Exclusion Criteria: No provision of informed consent',\n",
              " 'Inability to obtain signed informed consent from a parent or legal guardian.',\n",
              " 'Inclusion Criteria: Patient has provided informed consent.',\n",
              " 'Inclusion Criteria: Patient has provided IRB-approved written informed consent prior to conducting any study-related procedures',\n",
              " 'Inclusion Criteria: Patients having given their written informed consent  prior to participating in the trial.',\n",
              " 'Inclusion Criteria: provision of informed consent',\n",
              " 'Inclusion Criteria: Written informed consent',\n",
              " 'Inclusion Criteria: Written informed consent prior to any study related procedures',\n",
              " 'Inform consent',\n",
              " 'informed consent',\n",
              " 'Informed consent from the patients or authorized representatives must be obtained in writing enrollment into the study',\n",
              " 'Informed consent must be obtained from all subjects prior to beginning therapy',\n",
              " 'informed consent signed',\n",
              " 'Informed consent signed by the parent',\n",
              " 'Must sign an informed consent form',\n",
              " 'Patient must have given informed consent',\n",
              " \"Patient or patient's legally authorized representative has provided written informed consent\",\n",
              " 'Patient signs informed consent',\n",
              " 'Patients who sign and date a Patient Informed Consent form prior to the implant visit',\n",
              " 'Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study.',\n",
              " 'Provide informed consent',\n",
              " 'provide Informed Consent.',\n",
              " 'Provide written informed consent signed by patient or legal guardian prior to entering the study or undergoing any study procedures.',\n",
              " 'provision of informed consent',\n",
              " 'Separate written informed consent obtained before screening and study start respectively',\n",
              " 'Separate written informed consent obtained before screening and study start  respectively',\n",
              " 'Signed consent form',\n",
              " 'Signed informed consent',\n",
              " 'Signed informed consent obtained from the subjects (if possible) and their parents',\n",
              " 'Signed informed consent.',\n",
              " 'Signed written informed consent',\n",
              " 'Subject or parent/legally authorized representative has provided written informed consent',\n",
              " 'Subjects should read  sign and date an Informed Consent Form prior to any study procedures',\n",
              " 'Will provide written informed consent prior to their participation in the study.',\n",
              " 'Written informed consent',\n",
              " 'Written informed consent obtained before inclusion and randomization.',\n",
              " 'Written informed consent obtained from the parent or guardian of the subjects.',\n",
              " 'Written informed consent prior to entry into the study.',\n",
              " 'Written informed consent signed',\n",
              " 'Written  voluntary informed consent.',\n",
              " 'Exclusion Criteria: Implanted investigational drug eluting stents',\n",
              " 'intrauterine device (IUD)',\n",
              " 'Subject has a cardiac pacemaker or other implanted electro medical devices.',\n",
              " 'Patients requiring specialized endotracheal tubes',\n",
              " 'Have an active implantable device',\n",
              " 'Any implanted device or prosthesis or intrauterine IUD type of device',\n",
              " 'Condom or diaphragm',\n",
              " 'double barrier  .  condom  diaphragm with spermicide)',\n",
              " 'If patient uses a cane routinely in daily activities  then they can use it for their assessments',\n",
              " 'Admitted to the NICU',\n",
              " 'Have received intravascular contrast material within the preceding 14 days',\n",
              " 'Any patient undergoing screening and/or surveillance colonoscopy and/or upper endoscopy with possible biopsy or removal of tissue by polypectomy',\n",
              " 'A positive zidovudine (AZT) detection assay performed 7 days prior to drug dosing will exclude patients from study participation.',\n",
              " 'Exclusion Criteria: Screening clinical laboratory values',\n",
              " '[Note: If one of the two values is < 400 the patient will be excluded',\n",
              " 'Abnormal nasal epithelial TEPD total chloride conductance (a more electrically negative value than 5 mV for >= ???chloride-free+isoproterenol).',\n",
              " 'Must have a negative urine test for substances of abuse including marijuana  cocaine  cocaine derivatives  opiates and methadone',\n",
              " '2 positive Hepatitis B surface antigen results 6 months apart',\n",
              " 'Exclude if B12 less than 100 pg/ml (normal range greater than 200)',\n",
              " 'Expired breath CO level > 10 ppm and cotinine level > 210 ng/ml at the baseline measurement',\n",
              " 'Positive results of urine drug screen testing (amphetamines  benzodiazepines  cannabis  barbiturates  cocaine  opiates  antidepressants).',\n",
              " 'Positivity for HHV-8 antibodies and plasmaviremia (volunteers will be screened for anti-HHV-8 antibodies and positivity confirmed by PCR  only the individuals confirmed positive by PCR will be excluded)',\n",
              " 'Subjects who have experienced elevations in liver function test parameters on other cholinesterase inhibitors are still eligible.',\n",
              " 'triglyceride (TG) levels above 150 mg/dl ',\n",
              " '>= >= 5.0 ULN ',\n",
              " '1.5 x ULN',\n",
              " \"(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept 'blinded' until data analysis)\",\n",
              " 'Abnormal age adjusted immunoglobulin levels (IgG or IgA)',\n",
              " 'Note: creatinine clearance need not be determined if the baseline serum creatinine is within normal limits',\n",
              " 'All available prior computed tomography (CT) or magnetic resonance imaging (MRI) scans should be reviewed and noted  and measurements showing progression of disease should be documented whenever possible',\n",
              " '> than 1mm ST segment elevation or depression in at least two contiguous leads  new T waves inversion in two leads).',\n",
              " 'Concurrent Medication: Required for patients whose CD4 count falls below 200 cells/mm3:',\n",
              " 'Calcium less than the ULN',\n",
              " 'Exclude if folate less than 1.7 ng/ml (normal range greater than 1.9)',\n",
              " 'Subject exhibits viral strains that are resistant to lopinavir.',\n",
              " 'Patients with known positivity for human immunodeficiency virus (HIV) will be excluded due to possible pharmacokinetic interactions with bortezomib',\n",
              " 'They must also have a negative serum beta-human chorionic gonadotropin (B-hCG) at Screening',\n",
              " 'Documented to be HBsAg positive for > 6 months OR HBsAg positive and IgM anti-HBc negative and anti-HBs negative',\n",
              " 'Referring Pap smear was ASCUS  + HPV or LGSIL',\n",
              " 'Refraction with a spherical equivalent less than 5 Dp.',\n",
              " 'Stable hemodynamic condition: systolic blood pressure on arrival higher than 80 mmHg in the absence of continuous vasopressive drugs administration.',\n",
              " 'Wechsler Adult Intelligence Scale-Revised score < 70',\n",
              " 'A score of greater than 4 on the Modified Hachinski Ischemic Scale.',\n",
              " 'Any focal abnormality on neurologic exam.',\n",
              " 'Any subject with a screening resting systolic blood pressure >180 mmHg and/or resting diastolic blood pressure of >100 mmHg unless  in the opinion of the principal investigator  the blood pressures would not endanger the subject while participating in thi',\n",
              " 'AST and ALT >2.5 x ULN (AST and ALT >5 >=  ULN for subjects with liver metastasis)',\n",
              " 'Be immunosuppressed defined as having: CD4+(T4) lymphocytes = or < 400 cells/mm3.',\n",
              " 'Clinical laboratory tests (CBC  blood chemistries  urinalysis) taken at Visit 1 must have been within normal limits or clinically acceptable to the Investigator',\n",
              " 'Clinical laboratory tests (CBC  blood chemistries  urinalysis)must be within normal limits or clinically acceptable to the Investigator/Sponsor.',\n",
              " 'Clinically significant laboratory abnormalities.',\n",
              " 'Diagnosis and Criteria for Inclusion: Diagnosis: This study was designed for untreated subjects with primary hypercholesterolemia with plasma LDL-C concentrations between >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL) and triglyceride concentrations',\n",
              " 'Do not have a positive test for HIV virus  hepatitis C virus  or hepatitis B surface antigen',\n",
              " 'Exclude if T3 uptake is less than 19%',\n",
              " 'free T4 index is less than 0.8',\n",
              " 'HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive with positive HBsAg for the previous 6 months',\n",
              " 'If antibody-negative  patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.',\n",
              " 'If antibody-negative  patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.',\n",
              " 'If the patient fails this criterion  the Investigator may decide to conduct a 24-hour creatinine clearance test',\n",
              " 'Inclusion Criteria: >=18 years and <= 75 years of age with LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to <= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit) and triglyceride concent',\n",
              " 'Inclusion Criteria: >=18 years of age and treated with simvastatin 10 mg or 20 mg for at least 6 weeks and LDL-C levels of > 2.5 mmol/L to <=4.20 mmol/L (97 mg/dL to 160 mg/dL) at Visit 1.',\n",
              " 'Inclusion Criteria: Age 18-80 years  protein concentration in ascitic fluid < 15 g/L and at least one of the following: serum creatinine >=  1.2 mg/dl or BUN >=  25 mg/dl  serum sodium >= 130 mEq/L or severe liver failure as defined by a Child-Pugh s',\n",
              " 'Inclusion Criteria: Clinical diagnosis of ALS',\n",
              " 'Inclusion Criteria: Eligible subjects included men or women   passage of 3 or more unformed stools in the preceding 24 hours accompanied by one or more',\n",
              " 'Inclusion Criteria: Patients must meet all of the following conditions to be eligible for enrollment into the study: Diagnosis of CF based on conclusively abnormal sweat test (sweat chloride >35 mEq/liter.',\n",
              " 'Laboratory tests within the normal range of the laboratory (hematology  biochemistry  urinalysis) or within the acceptable range per agreement between investigator and sponsor.',\n",
              " 'Less than 5th percentile in birthweight and head circumference for gestational age',\n",
              " 'LVEF normal',\n",
              " 'Mini-Mental State Examination score at screening visit greater than 14',\n",
              " 'Modified Hachinski Ischemic Index less than or equal to 4',\n",
              " 'Must have coagulation parameters within the limits of normal for the testing facility',\n",
              " 'Must have serum chemistry values and urinalysis values within the limits of normal for the testing facility',\n",
              " 'OR more than 3 mutations from the other points of the LPV mutation score:10 20 24 46 53 54 63 71',\n",
              " 'Oxygen saturation >= 92% on room air.',\n",
              " 'Patient has any abnormal chemistry or hematology results that are deemed by the Investigator to be clinically significant.',\n",
              " 'Patient has pain intensity score of at least 4 on the 11-point Likert numerical rating scale at screening',\n",
              " 'Patients may be HBeAg positive  and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive.',\n",
              " 'Patients must have: Positive HIV antibody test results by ELISA.',\n",
              " 'Patients with contra-indications for multiple biopsies',\n",
              " 'Positive hepatitis B surface antigen  hepatitis C antibody test  or HIV test.',\n",
              " 'Satisfactory medical assessment with no clinically significant or relevant',\n",
              " 'Score of >= 11/14 on Section C (hand) of UE portion of Fugl Meyer Assessment (FMA)',\n",
              " 'Subjects must have normal or clinically acceptable physical exam and ECG intervals (PR  QRS  QT and QTc) on 12-lead ECG (recorded at 25 mm/s).',\n",
              " 'Subjects with controlled diabetes prior to entry must have a mean sitting after 5 minute of rest systolic/diastolic office blood pressure >= 128/78 mmHg from non-dominated arm',\n",
              " 'T4 less than 2.9 ((g/dL)',\n",
              " 'Weighing at least 60 kg  who are within 10% of their ideal weights ',\n",
              " 'Weighing at least 60 kg  who are within 10% of their ideal weights ',\n",
              " '(If the patient awakens with a deficit  time of onset is considered the time the patient was last seen functioning normally.)',\n",
              " '[Note: If one of the two values is < 400 the patient will be excluded',\n",
              " '<12 months post-partum*>= ',\n",
              " '> than 1mm ST segment elevation or depression in at least two contiguous leads  new T waves inversion in two leads).',\n",
              " '>= 5.0 ULN ',\n",
              " '>=  21 days since completion of prior chemotherapy  >= 6 weeks since prior Mitomycin-C',\n",
              " '>=  50% stenosis for symptomatic subjects',\n",
              " '>=  80% stenosis for asymptomatic subjects or',\n",
              " '1.5 x ULN',\n",
              " '20 000/mL',\n",
              " '50 copies/ml for the last 6 months on HAART therapy.',\n",
              " '500 cells/mL',\n",
              " '500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios',\n",
              " '50mL to 300mL of whole blood within 30 days  301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..',\n",
              " '50mL to 300mL of whole blood within 30 days  301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..',\n",
              " '5x Upper Limit of Normal (ULN)',\n",
              " '8.0 g/dL',\n",
              " 'A CD4+ count between 200 and 500 cells/mm3.',\n",
              " 'A minimum score of 20 on the YMRS (Youngs Mania Rating Scale).',\n",
              " 'A minimum time period of 3 weeks should elapse between the completion of extensive radiation therapy for recurrent/metastatic disease and enrollment in the study.',\n",
              " 'A Positive and Negative Syndrome Scale (PANSS) total score between 60 (included) and 120 (excluded)',\n",
              " 'A Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure  unless the CK and CK-MB enzymes or Troponin levels are less than twice the Upper Normal Limit',\n",
              " 'A significant (> 50%) stenosis proximal or distal to the target lesion',\n",
              " 'Abnormal liver function (serum total bilirubin > the upper limit of normal  or serum ALT  AST  or GGT >2.0 times the upper limit of normal).',\n",
              " 'Abnormal renal function (serum creatinine >1.5 times upper limit of normal).',\n",
              " 'Abnormal thyroid function tests within the last 6 months',\n",
              " 'Absolute granulocyte count >=  1 500/mm??',\n",
              " 'Absolute neutrophil count (ANC) > 1 500/mm3  platelets > 100 000/mm3  and hemoglobin > 9 g/dl',\n",
              " 'Absolute neutrophil count<750 cells/ul',\n",
              " 'Acceptable hematologic status: Absolute neutrophil count (ANC) >=  1500 cells/mm(3) (1.5 >= 10(9)/L)',\n",
              " 'Acceptable liver function: Bilirubin >= 1.5 times upper limit of normal (ULN)',\n",
              " 'Acceptable renal function: For all patients serum creatinine within normal limits  OR calculated creatinine clearance >=  60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.',\n",
              " 'Activated partial thromboplastin time (aPTT) >1.5 >=  ULN',\n",
              " 'Active malignancy of cervix  uterus  fallopian tube(s) or ovary > Stage I  or bladder of any Stage',\n",
              " 'Adequate bone marrow reserve: (Haemoglobin >=  12g/l  Absolute Neutrophil Count (ANC) >=  2.0x 10^9  Platelets >= 100 000)',\n",
              " 'Adequate organ function that has been determined within 7 days prior to enrollment  defined as:Leucocyte count > 3 000/uL',\n",
              " 'All patients must be diagnosed as having hypertension: For this project  hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention  Detection  Evaluation and Treatment of H',\n",
              " 'All patients must be diagnosed as having hypertension: For this project  hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention  Detection  Evaluation and Treatment of H',\n",
              " 'Allowed: PCP prophylaxis (required for patients with CD4 count < 200 cells/mm3).',\n",
              " 'ALT greater than 3xULN.',\n",
              " 'ALT or AST > 5x Upper Limit of Normal (ULN)',\n",
              " 'ALT/AST < 5 times x UNL  bilirubin < 1.5times x UNL  creatinine < 1.25 times x UNL  normal calcium level',\n",
              " 'Ambulatory performance score of = or > 70 Karnofsky.',\n",
              " 'An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size  or a recent history of unintentional weight loss of 10% from the subjects baseline',\n",
              " 'Anatomic criteria :length of aortic proximal neck >10 mm  diameter of aortic proximal neck < 32 mm  Absence of aortic neck angulation > 90>=  and patent iliac without important stenosis or tortuosity.',\n",
              " 'ANC > 1 500/ul',\n",
              " 'ANC > 500/mm^3',\n",
              " 'ANC ?? 1500/ul  platelet count ?? 100 000/ul',\n",
              " 'And modifications of ST-T (no persistent ST elevation) on 12-lead EKG ',\n",
              " 'And presence of >= 1 de novo stenosis(es) >50% located on >= 1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.',\n",
              " 'And presence of >= 1 de novo stenosis(es) >50% located on >= 1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.',\n",
              " 'and systolic blood pressure consistently < 90 mmHg',\n",
              " 'Anemia (hemoglobin < 8.5 g/dl)',\n",
              " 'Anemia defined as a hematocrit of < 30 and hemoglobin < 10g/dL.',\n",
              " 'Angiographic exclusion criteria (as determined >= 30 days prior to procedure): The target carotid artery is completely occluded.',\n",
              " 'Angiographic exclusion criteria: Unprotected left main coronary artery disease with >=  50% stenosis',\n",
              " 'Angiographic inclusion criteria (as determined >= 30 days prior to procedure): Target lesion stenosis (% stenosis = (1-N/D) X 100)1  documented by selective angiography pre-intervention  is 1.1',\n",
              " 'Any one of the following criteria: Diabetes  CRP >= 2 mg/L  or metabolic syndrome',\n",
              " 'Any patient who has a platelet count < 100 000 cells/mm3 or > 700 000 cells/mm3 or a WBC of < 3 000 cells/mm3',\n",
              " 'Are (1)NYHA Class IV or (2)NYHA Class III with highest calculated CrCl  60mL/min within the previous 30 days',\n",
              " 'Are of 40 kg (88 pounds) of weight or more.',\n",
              " 'AST (SGOT)  ALT (SGPT) and alkaline phosphatase >= 2.5 times ULN (if liver metastases are present  then >= 5 >=  ULN is allowed).',\n",
              " 'AST and ALT levels which are less than or equal to 10 times the upper limit of normal.',\n",
              " 'AST or ALT < 2 times ULN (unless related to primary disease)',\n",
              " 'AST or ALT < 5 times upper limit of normal',\n",
              " 'Asymptomatic patients with a stenosis greater than 80% by ultrasound or angiography performed in previous 30 days',\n",
              " 'At least 1 measurable target lesion in accordance with RECIST criteria to assess clinical response (tumors within a previously irradiated field are designated as non-target).',\n",
              " 'At least moderately concerned about gaining weight after quitting smoking',\n",
              " 'At least one bidimensionally measurable lesion with clearly defined margins documented by: medical photograph for skin and oral lesions  plain X-ray with at least one diameter 0.5 cm or greater  CT  MRI  or palpation with both diameters 2 cm or greater',\n",
              " 'At the time of inclusion (>=  1 day post PCI) patient does no longer require i.v',\n",
              " 'Average of CD4+ cell count at 60 and at 21 days prior to study beginning = or < 400 cells/mm3.',\n",
              " 'Axillary temperature >= 37.5oC but less than 40 oC or history of fever in preceding 24 hr.',\n",
              " 'Baseline NIHSS score at least 2 points  not more than 21 points',\n",
              " 'Baseline serum osmolarity of greater than 310 mOsm/L',\n",
              " 'Be admitted to the hospital within 36 hours of the mandatory dose of IV furosemide 40 mg at between 2000 and 2200 hour on Day -1',\n",
              " 'Be immunosuppressed defined as having CD4+(T4) lymphocytes = or < 400 cells/mm3  based on two measurements at least 1 week apart.',\n",
              " 'Best Corrected Visual acuity >20 /25',\n",
              " 'bifurcation lesions (side branch > 2 0 mm)',\n",
              " 'Bilirubin < 2 mg/dL',\n",
              " 'Bilirubin >= 1.5 times the upper limit of normal (ULN)',\n",
              " 'Bilirubin less than or equal to 1.5 mg/dL',\n",
              " 'Bladder capacity > 200cc (by any method)',\n",
              " 'blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic ',\n",
              " 'BNP levels equal to or greater than 300 pg/ml.',\n",
              " 'Body weight >= 25 kg.',\n",
              " 'Bone marrow involvement (< 25% neuroblasts) by morphologic exam within the past 2 weeks',\n",
              " 'BPI 12 <= 4 (pain scale)',\n",
              " 'Calculated creatinine clearance of less than 30 ml/min or serum creatinine > 3 mg/dL',\n",
              " 'Calculated LDL-C concentration of at least 2.6 and 4.1mmol/l or less using the Friedewald equation  and triglyceride of less than 3.99 mmol/l',\n",
              " 'Calgary Depression scale score >10 or Simpson-Angus Rating Scale score > 20',\n",
              " 'CD4 cell count >100 cells/mL at screening',\n",
              " 'CD4 count 300-600 cells/mm3.',\n",
              " 'central venous pressure consistently < 6 mmHg',\n",
              " 'Chronic oral daily requirement of 80-240 mg of furosemide for at least 7 days before the study start',\n",
              " 'CKD stage 3 (GFR 30 - 59 ml/min) for CKD group',\n",
              " 'Clinical laboratory values must meet the following: Granulocytes greater than or equal to 1 500/mm(3)',\n",
              " 'Clinically significant anemia (HCT < 33%)',\n",
              " 'clinically significant diameter of stenosis (50-99 % according to visual assessment of operator)',\n",
              " 'combination of points 1 - 4',\n",
              " 'Common carotid artery diameter where the Mo.Ma device will be positioned is 5-13 mm.',\n",
              " 'Complete blood count and differential defined as: Hematocrit >= 30% for women  >= 38% for men',\n",
              " 'Corrected QT interval < 0.47 seconds',\n",
              " 'Creatinine > 1.5 x ULN',\n",
              " 'Creatinine >= 1.5 times ULN',\n",
              " 'Creatinine >= 2.0 mg/dL OR creatinine clearance >=  40 mL/min',\n",
              " 'Creatinine clearance less than 50 ml/min',\n",
              " 'Creatinine clearance or radioisotope GFR >=  60 mL/min',\n",
              " 'Creatinine less than or equal to 1.6 mg/dL',\n",
              " 'Creatinine within normal institutional limits or creatinine clearance (CrCl) greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal',\n",
              " 'currently taking atorvastatin 10 mg daily and history has taken 80 % of daily doses for the preceding 6 weeks prior to Visit 3',\n",
              " 'D in one eye (non-stud eye) and the presence of the following characteristics in the second eye (study eye  eye to be treated): At least 5 or more intermediate (> 63 ??m) or larger soft drusen AND/OR Confluent drusen within 3000 ??m of the fovea center',\n",
              " 'Decreased helper/suppressor ratio < 1.0.',\n",
              " 'Diagnosis of high-risk neuroblastoma  meeting one of the following criteria: Refractory disease  defined as no response  mixed response  or progressive disease after completion of induction therapy administered according to clinical trials COG-A3973 or CO',\n",
              " 'Differential within institutional normal limits or approval of site physician',\n",
              " 'Dilatation of the pupil < 5 mm',\n",
              " 'Dilatation of the pupil < 5 mm',\n",
              " 'Dilatation of the pupil < 5 mm.',\n",
              " \"Discharge to a skilled nursing facility or long-term care facility (EXCEPTION: Subjects may be d/c'd to the 6A SNF unit at MetroHealth Medical Center)\",\n",
              " 'Documentation of left ventricular ejection fraction (LVEF) less than or equal to 40% measured by nuclear scan  echocardiogram (ECHO)  or ventriculogram  within 90 days prior to surgery.',\n",
              " 'Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication',\n",
              " 'Donation of plasma (500 mL) within 7 days prior to drug administration',\n",
              " 'Donation of plasma (500 Ml) within 7 days to drug administration',\n",
              " 'Donation of plasma (500 Ml) within 7 days to drug administration',\n",
              " 'Donation or loss of hole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.',\n",
              " 'Donation or loss of whole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.',\n",
              " 'Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study)prior to the administration of the study medication (50 mL to 300 mL of whole blood within 30 days  301 mL to 500 mL of whole b',\n",
              " 'Doppler index < 0 8',\n",
              " 'Duration of insomnia complaint >1 month',\n",
              " 'ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg  diastolic blood pressure lower than 60 or over 90 mmHg  or heart rate less than 60 or over 100 bpm) at screening.',\n",
              " 'ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg  diastolic blood pressure lower than 60 or over 90 mmHg  or heart rate less than 60 or over 100 bpm) at screening.',\n",
              " 'ECOG (Eastern Cooperative Oncology Group) status: 0-1-2',\n",
              " 'ECOG 0-2',\n",
              " 'ECOG performance status < 2 (Appendix 1).',\n",
              " 'ECOG Performance Status >=1.',\n",
              " 'ECOG Performance Status 0-1',\n",
              " 'ECOG performance status 0-2',\n",
              " 'ECOG performance status 0-2',\n",
              " 'ECOG performance status 0-2 .',\n",
              " 'ECOG score < 0 to 2',\n",
              " 'ECOG score to be equal to or above 2',\n",
              " 'Ejection fraction < 40%',\n",
              " 'Ejection fraction >= 30%',\n",
              " 'Ejection fraction >=  50%',\n",
              " 'ET-743 at any time (Stage 1 only).',\n",
              " 'either HIV-seropositive  CD4+ T-cell count of >=350/mm3',\n",
              " 'Evidence of impaired renal function (eGFR <60 ml/min)',\n",
              " 'EXCLUSION CRITERIA include: Impaired renal function  demonstrated by creatinine clearance < 30 ml/min',\n",
              " 'Exclusion Criteria: Conditions associated with elevated TGF-Beta  ',\n",
              " 'Exclusion Criteria: Have systolic blood pressure consistently <90mm Hg',\n",
              " 'Exclusion Criteria: Patients < 5 ans or > 65 ans',\n",
              " 'Exclusion Criteria: Planned aortic valve replacement or repair',\n",
              " 'Exclusion Criteria: Severe Hypertension defined by PAS > 180mmHg and/or PAD > 110 mmHg.',\n",
              " 'Exclusion Criteria: Subjects who do not have a FEV1/forced vital capacity (FVC) ratio of >=70% at Visit 1.',\n",
              " 'External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm.',\n",
              " 'Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5',\n",
              " 'falciparum of between 250 and 100 000 asexual parasites/mm3 as determined by microscopic exam of the thick or thin smear',\n",
              " 'fasting blood sugar greater than 110 mg/dl',\n",
              " 'Fasting triglyceride levels of >= 400 mg/dL (4.5 mmol/L)',\n",
              " 'FEV_1 and DLCO >=  30% OR normal chest x-ray  pulse oximetry  and venous blood gas',\n",
              " 'Forced vital capacity 50+%',\n",
              " \"Functionality score ('Get-up-and-Go' test) must be > 10.0 sec but < 20.0 sec\",\n",
              " 'Granulocytes >= 1 500/ul  Platelets >= 100 000/ul  Creatinine >=ULN  Bilirubin >=1.5 mg/dl  AST >=2.5 x ULN',\n",
              " 'has a history of renal failure and a serum creatinine value greater than 3.0 mg/dl',\n",
              " 'has uncontrolled diabetes  defined as a documented plasma blood glucose value > 400 mg/dl (22.2 mmol/L) within three (3) days before surgery',\n",
              " 'Have 2 measurements of viral load (amount of HIV in the blood) during the 6 months before entering the study that are below 400 copies/ml by RT-PCR test or below 500 copies/ml by branched DNA test  measured at least 8 weeks apart.',\n",
              " 'Have a CD4 cell count of 200 copies/ml or higher within 60 days of study entry.',\n",
              " 'Have a CD4+ count of 50 cells/mm3 or more.',\n",
              " 'Have a Left Ventricular Ejection Fraction less than 40% (measured within 24 weeks before randomization)',\n",
              " 'have a systolic/diastolic blood pressure <= 140/90 mm Hg',\n",
              " 'Have a viral load below 50 copies/ml within 30 days prior to entry.',\n",
              " 'Have an HIV count of 5 000 copies/ml or more within 30 days prior to study entry.',\n",
              " 'Hb>10g/dl.',\n",
              " 'HbA1c > 10%',\n",
              " 'HbA1c > 7.5%',\n",
              " 'heart rate < 55 beats per minute',\n",
              " 'Hematocrit > 29%  ANC > 1 500  platelets > 125 000',\n",
              " 'Hemoglobin <10 g/dL.',\n",
              " 'Hemoglobin <8.5 g/dL (hemoglobin may be supported by transfusion  erythropoietin  or other approved hematopoietic growth factors',\n",
              " 'Hemoglobin > 10 g/dL',\n",
              " 'Hemoglobin >= 9.5 g/dL',\n",
              " 'Hemoglobin  >= 9 g/dL',\n",
              " 'Hemoglobin  >= 9 g/dL.',\n",
              " 'Hemoglobin greater than or equal to 9 g/dL',\n",
              " 'Hemoglobin should be >8 g/dL.',\n",
              " 'HER2-positive  defined 3+ by IHC or HER2 gene amplification by FISH',\n",
              " 'Hgb >=  10 g/dl  BUN < 25 mg and creatinine < 1.5 mg',\n",
              " 'high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women ',\n",
              " 'HIV RNA <100 000 copies/mL',\n",
              " 'hospitalisation for less than 3 nights',\n",
              " 'hospitalised in internal medicine',\n",
              " 'Hypercalcemia (serum) > 2.75 mmol/l in three independent measurements during 10 days',\n",
              " 'If abnormal laboratory results such as : Hb<8 g/dl',\n",
              " 'If presence of the following mutations : in the protease : one among 32 47 48 50 82 84 90',\n",
              " 'Impaired hepatic function (AST/SGOT or ALT/SGPT > 2 times the upper limit of the reference range)',\n",
              " 'Impaired hepatic function (liver enzymes greater than the upper limit of normal or bilirubin outside the normal range).',\n",
              " 'Impaired renal function (creatinine > 2 mg/dl) at the time of cell therapy',\n",
              " 'Impaired renal function (creatinine > 3.0 mg/dl or 265 ??mol/l)',\n",
              " 'in the reverse transcriptase : 215 or 184.',\n",
              " 'Inclusion Criteria: BW below 1 500 gm',\n",
              " 'Inclusion Criteria: HBV DNA positive with DNA levels at screening greater than or equal to 3 000 000 copies/mL.',\n",
              " 'Inclusion Criteria: Patient with left ventricular systolic dysfunction  left ventricular ejection fraction >=35%  as documented at the moment of ICD implant',\n",
              " 'Inclusion Criteria: Patient with mild or moderate hypertension defined with arterial diastolic pressure (PAD) at sit position between 90 mmHg and 110 mmHg and arterial systolic pressure (PAS) at sit position between 140 mmHg and 180 mmHg.',\n",
              " 'Inclusion Criteria: Two mandibular third molars containing at least one mesially angular impaction with crown exposed to oral cavity',\n",
              " 'Inclusion Criteria: visual acuity worse than 20/40  caused by central subepithelial fibrosis',\n",
              " 'Individuals diagnosed with osteoporosis  .  bone density of hip greater than 2.5 standard deviations below the mean) will not be enrolled in the study',\n",
              " 'International normalized ratio (INR) >1.5',\n",
              " 'irradiation to 25% of bone marrow-containing areas  or',\n",
              " 'Karnofsky/Lansky performance status 60-100%',\n",
              " 'Kidney function: stadium 1-4.',\n",
              " 'Laboratory evidence of hematologic disease (absolute leukocyte count <4000/mm3 or >14 500/mm3  absolute lymphocyte count <1500/mm3  platelet count <120 000/mm3  or hemoglobin <10.0 g/dL).',\n",
              " 'Laboratory evidence of hematologic disease (absolute leukocyte count 3.5-11/ul  absolute lymphocyte count 560-5280/ul  platelet count 120 000-400 000/ul  or hemoglobin 10.0-16.5g/dL).',\n",
              " 'Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).',\n",
              " 'Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).',\n",
              " 'Laboratory values within the following limits: Hemoglobin > 10.0 g/dL Neutrophil count > 1.5 x l09/L Lymphocyte count > Lower limit of institutional normal Platelet count > 80 x l09/L Serum creatinine < 2.0 mg/dL Serum bilirubin < 2 x upper limit of insti',\n",
              " 'Large (>=  3 cm) breast cancer',\n",
              " 'LDL-C >200 mg/dL (5.2 mmol/L)',\n",
              " 'LDL-C concentration greater than or equal to 2.5 mmol/L to less than or equal to 160 mg/dL (less than or equal to 4.1 mmol/L) based on blood specimens taken at Visit 1  using the Friedewald calculation as described in the Protocol Section 8.8',\n",
              " 'Left ventricular ejection fraction (LVEF) <55%',\n",
              " 'Left ventricular ejection fraction <50%',\n",
              " 'Left ventricular systolic dysfunction as evidenced by left ventricular ejection fraction < 40%  measured using contrast or radionuclide ventriculography or by echocardiography  within 180 days of the study start',\n",
              " 'lesion must be covered by stent length of no more than 24 mm and stent diameter of no more than 3 5 mm',\n",
              " 'liver transaminases (ALT  AST) < 50 % above the upper limit of normal  with no active liver disease  and CK < 50 % above the upper limit of normal at Baseline Visit.',\n",
              " 'Liver transaminases (ALT  AST) less than 50% above the upper limit of normal  with no active liver disease  and CPK less than 50% above the upper limit of normal as tested in blood specimens taken at Visit 1',\n",
              " 'Lumbar spine or total hip BMD T-score 1ess than or equal to -2.0 and >/= 1 prevalent osteoporotic fracture  or lumbar spine or total hip BMD T-score less than or equal to -2.5 with or without and >/= 1 prevalent osteoporotic fracture',\n",
              " 'Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight).',\n",
              " 'Massive stroke (> 2/3 MCA territory) or any amount of midline shift due to cerebral edema on head CT.',\n",
              " 'Maximal cardiac troponin elevation >=  4 (measured at 37>=  C)',\n",
              " 'Medical disorder that would influence outcome of the study - e.g',\n",
              " 'More than 12 weeks (was 24 weeks  AMENDED 3/31/96) of total prior AZT ( > 500 mg/day without serious adverse event)',\n",
              " 'Morning FEV1 of 40-80% normal.',\n",
              " 'Must have anatomic stenosis greater than 70% by ultrasound or angiography performed in previous 30 days',\n",
              " 'Must have at least 1 of the following pancreatic manifestations of VHL documented by a non-invasive imaging study: Pancreatic cyst(s)',\n",
              " 'Nephropathy (proteinuria >500 mg/day)',\n",
              " 'NIHSS must be > 4 points.',\n",
              " 'No more than 3 sites of skeletal disease as determined by an >= I-MIBG scan (for regional involvement of the skeleton [e.g.  pelvis  spine]  the tumor involvement should be < 25% of the site)',\n",
              " 'Normal ALT (as defined by the range of the clinical site laboratories) and Creatinine (<= 1.6 mg/dL)',\n",
              " 'Normal amplitude of accommodation',\n",
              " 'Normal best-corrected visual acuity at 20/40 or better',\n",
              " 'or if serum creatinine > upper limit of normal  a calculated creatinine clearance < 60 mL/min/1.73 m2).',\n",
              " 'Patient has a Karnofsky Performance Status greater than or equal to 60%',\n",
              " 'Patient has an estimated creatinine clearance of < 60 ml/min calculated using the Cockroft Gault method',\n",
              " 'Patient in ability to undergone hepatic or pulmonary resection in case of recurrence during the follow-up (ECOG >= 2)',\n",
              " 'Patient with elevated Prostate Specific Antigen (PSA)',\n",
              " 'Patient with serum creatinine > 2 mg/dl or creatinine clearance < 60 ml/min',\n",
              " 'Patients ever having had a value of CD4+ T cell number < 250 will be excluded]',\n",
              " 'Patients must have an ECOG performance status of <2 (ECOG criteria published in [46])',\n",
              " 'Patients must have an ECOG performance status of less than or equal to 1.',\n",
              " 'Patients must have ECOG performance status 0-2.',\n",
              " 'Patients must have had a colonoscopy within the past 5 years',\n",
              " 'Patients must have normal organ and marrow function (as defined below) measured within one week prior to registration: Absolute neutrophil count >1 500/mm3.',\n",
              " 'Patients should have adequate organ function related to the following: White count > 3000/ul  Platelet count > 70 000/ul  Hemoglobin > 8 g/l  Bilirubin WNL  AST and ALT < 2.5 x ULN  and Creatinine < 1.5 x ULN or 24 hour creatinine clearance > 60 ml/min',\n",
              " \"Patients with clinically significant ECG abnormality  including prolonged QTc (defined as QTc >=450 msec using Fridericia's correction).\",\n",
              " 'Patients with X-ray findings of acute fractures  severe loss of bone density  avascular necrosis and/or severe bone or joint deformity.',\n",
              " 'Performance Status',\n",
              " 'Performance status 0-2',\n",
              " 'Performance status contraindicating a hepatic or pulmonary surgery in case of recurrence.',\n",
              " 'Performance status Not specified',\n",
              " 'Performance status of 0-1',\n",
              " 'Plasma HIV-1 viremia levels <= 50 000 copies/mL',\n",
              " 'Platelet count < 100 000/ul',\n",
              " 'Platelet count <75 000/ul',\n",
              " 'Platelet count >',\n",
              " 'Platelet count  >= 100 000 platelet/mm(3) (100 >= 10(9)/L)',\n",
              " 'Platelet count  >= 100 000/mm??',\n",
              " 'Platelet count  >= 100 000/ul',\n",
              " 'Platelet count<50 000/ml',\n",
              " 'Platelets >= 100 000/mm3',\n",
              " 'Platelets greater than or equal to 100 000/mm(3)',\n",
              " 'Platelets greater than or equal to 100 000/mm3.',\n",
              " 'Poorly controlled hypertension  .  blood pressure: systolic >180 mm Hg or diastolic >100 mm Hg).',\n",
              " \"Positive infectious disease markers from mother's blood or cord at time of -collection (See below for details).\",\n",
              " 'Presence of hypoalbuminaemia < 35 g/L',\n",
              " 'Presence of serious acute infection requiring parenteral treatment at time of study entry.',\n",
              " 'Presence of serious acute infection requiring parenteral treatment at time of study entry.',\n",
              " 'Presenting for CABG with or without mitral valve repair or replacement procedure',\n",
              " 'Previous enrollment in LABS-1',\n",
              " 'Previously performed stem / mononuclear cell therapy',\n",
              " 'PSA value equal to or above 2 ng/ml',\n",
              " 'PT-INR/PTT < 1.5 x upper limit of normal.',\n",
              " 'Radiation therapy to greater than or equal to 50% of the bone marrow',\n",
              " 'range of reference diameter 2.5 to 4.0mm',\n",
              " 'Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication',\n",
              " 'Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication',\n",
              " 'Reference vessel diameter >=  2.5 and >= 3.75 mm by visual estimate',\n",
              " 'remnant liver volume < 50%',\n",
              " 'remnant liver volume >= 70%',\n",
              " 'Renal anemia with hemoglobin (blood) < 10 mg/dl',\n",
              " 'Renal failure (serum creatinine stably > 1.7 mg/dl',\n",
              " 'Reported a stable weight history for at least 4 weeks prior to randomization at Visit 3 (baseline visit)',\n",
              " 'Required Initial Laboratory Data: *ANC >=  1 500/mm3  *Platelet count >=  100 000/mm3  *SGPT < 1.5 times ULN  *Alkaline phosphatase < 2.0 times ULN  *Bilirubin < 1.5 mg/dl  *Serum creatinine < 1.5 times ULN',\n",
              " 'Screening clinical laboratory values: Absolute neutrophil count <1500/ul',\n",
              " 'Serum albumin <2.5 g/dL.',\n",
              " 'Serum bilirubin < 1.5 times ULN',\n",
              " 'Serum creatinine < 1.5 mg/dl  BUN < 25 mg/dl  serum SGOT and bilirubin < 1.5 times upper limit of normal',\n",
              " 'Serum creatinine < 1.5 times ULN  or 24-hour creatinine clearance > 75 cc/min',\n",
              " 'serum creatinine > 175 ??mol/L',\n",
              " 'Serum creatinine >2.0 mg/dL',\n",
              " 'Serum creatinine greater then 2 mg/dl.',\n",
              " 'Serum Glutamate Pyruvate Transaminase (SGPT) >= 2.5 ULN  Serum Glutamate Oxaloacetate Transaminase (SGOT) >= 2.5 ULN ',\n",
              " 'serum glutamyloxaloacetic transaminase (SGOT) < 2.5 ULN',\n",
              " 'Serum potassium > 3.5 mEq/L.',\n",
              " 'Serum potassium > 5.2 meq/L',\n",
              " 'Seven of 10 patients in each treatment arm must have p24 antigen levels = or > 70 pg/ml (> 50 pg/ml at U',\n",
              " 'Severe disorders of lipoprotein metabolism (Low-density lipoprotein cholesterol (LDL)> 5.0 mmol/L)',\n",
              " 'Severe renal insufficiency /se creatinine greater than or equal to 150 umol/l/',\n",
              " 'SGOT and SGPT >= 2.5 times upper limit of normal',\n",
              " 'SGOT and/or SGPT > 1.5 upper limit normal  associated with Alk.phosph > 2.5 ULN',\n",
              " 'SGOT less than 2.0 x ULN',\n",
              " 'Shortening fraction >=  25% by ECHO OR ejection fraction > 30% by MUGA',\n",
              " 'Show evidence of mild cognitive impairment (MCI) by meeting all of the following criteria: Global CDR score = 0.5  NYU Delayed Paragraph Recall less than 9  17-item HAM-D score less than 13  and HAM-D Item 1 (depressed mood) score =1.',\n",
              " 'Show evidence of significant active hematological disease such as a white blood cell (WBC) count <= 2500/ul (2.50 1E+09/L)  an absolute neutrophil count <= 1000/ul (1.00 1E+09/L)  or a platelet count <100 000/mm^3.',\n",
              " 'Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL or transaminase (ALT  AST) elevations greater than 2 times the upper limit of the laboratory reference range.',\n",
              " 'Significant regional wall motion abnormality on echocardiography at the time of acute PCI (ejection fraction >= 50% on visual estimation).',\n",
              " 'Significant renal impairment  .  creatinine clearance < 45 mL/min by the Cockcroft-Gault formula)  or changing renal function during the 7 days before study start  or intrinsic renal disease',\n",
              " 'Stable elevations of liver enzymes  alanine aminotransferase (ALT)  and aspartate aminotransferase (AST) due to concomitant medications will be allowed if they are less than 2 times the ULN.',\n",
              " 'Stimulated C-peptide > 0.2pmol/L on MMTT',\n",
              " 'study participants had to have a normal Pap smear within the previous 12 months',\n",
              " 'Subject had abnormal pre-intervention blood counts with platelets < 50 000/cubic mm or > 700 000/cubic mm or white blood cell count < 3 000/cubic mm.',\n",
              " 'Subject has a Karnofsky Score &#8805',\n",
              " 'Subject has any of the following abnormal laboratory test results at screening: Hemoglobin &lt',\n",
              " 'Subject has severe chronic renal failure (creatinine > 2.5 mg/dl).',\n",
              " 'Subject is &#8805',\n",
              " 'Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.',\n",
              " 'Subject must have an undetectable viral load (VL) &lt',\n",
              " 'Subjects must have a baseline FEV1 of >=65% of predicted normal value at Visit 1.',\n",
              " 'Subjects must have a FEV1 >=  0.70L at Visit 1.',\n",
              " 'Subjects must have an LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to <= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).',\n",
              " 'Subjects must have an LDL-C concentration >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).',\n",
              " 'Subjects must have liver transaminases (ALT  AST) < 50% above the upper limit of normal  with no active liver disease  and CK < 50% above the upper limit of normal at Visit 3 (Baseline Visit).',\n",
              " 'Subjects must have liver transaminases (ALT  AST) <50% above the upper limit of normal  with no active liver disease  and CK <50% above the upper limit of normal at Visit 3 (Baseline Visit).',\n",
              " 'Subjects must have triglyceride concentrations of < 3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).',\n",
              " 'Subjects must have triglyceride concentrations of <3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).',\n",
              " 'Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline visit).',\n",
              " 'Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline Visit).',\n",
              " \"Subject's serum AST and ALT levels must be &lt\",\n",
              " 'Subjects who do not have a ??15 pack-year smoking history and a baseline breathlessness severity grade of ??2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visit 1.',\n",
              " 'Subjects who  through completion of the study  would have donated in excess of 500 mL blood in 14 days  or 500-750 mL blood in 14 days (unless approved by the Principal Investigator  1000 mL blood in 90 days  1250 mL blood in 120 days  1500 mL blood in 18',\n",
              " 'Subjects who  through completion of the study  would have donated in excess of 500 mL blood in 14 days  or 500-750 mL of blood in 14 days (unless approved by Principal Investigator  1000 mL blood in 90 days  1250 mL blood in 120 days  1500 mL blood in 180',\n",
              " 'Subjects with no stenosis or stenosis <50% on angiography',\n",
              " 'Subjects with serum creatinine greater than 3.',\n",
              " 'Subjects with serum total bilirubin greater than 4.',\n",
              " 'Systolic blood pressure (SBP) consistently < 90 mm Hg',\n",
              " 'systolic blood pressure < 105 mm Hg',\n",
              " 'Systolic blood pressure greater > 200 mm Hg or MAP > 120 mm HG when patient is initially monitored.',\n",
              " 'Target lesion involves bifurcation class D & type G including a side branch >=  2.5mm in diameter (either stenosis of both main vessel and major side branch or stenosis of just major side branch) that would require stenting of diseased side branch',\n",
              " 'Target lesion stenosis is >= 50% and <100% (minimum TIMI flow I at the time of the PCI procedure) (visual estimate)',\n",
              " 'Target lesion(s) is(are) located in a native coronary artery  which can be covered by one single stent of maximum 33 mm',\n",
              " 'The coronary artery lesion should be >=27 mm in length (a margin of 3mm proximal and 3mm distal is recommended) and should be entirely covered by one single Genous Bio-engineered R stentTM',\n",
              " \"The inability to position a stiff .035' guidewire in the external carotid artery (ECA).\",\n",
              " 'The investigators will also exclude subjects with hematocrit < 30%.',\n",
              " 'The laboratory values used for exclusion of subjects will be fasting glucose > 110 mg/dl  glycosylated hemoglobin (HgBA1) > 6.5%  serum creatinine > 1.5 mg/dl  ALT or AST > 2x the upper limit of normal  cholesterol > 250 mg/dl',\n",
              " 'the need for urgent intervention  defined according to the American College of Cardiology/ American Heart Association (ACC/AHA) guidelines as being patients who are required to stay in the hospital  but may be scheduled and operated on within a normal sch',\n",
              " 'The patient would be allowed to enroll in the study if the 24-hour test result is < 60 ml/min.',\n",
              " 'The presence of severe renal impairment (CrCl <30 mL/min or creatinine >3 x ULN)  nephrotic syndrome  or patients undergoing dialysis',\n",
              " 'Thrombocytopenia (plt < 100 k)  PTT > 100 sec  INR > 3.0 at time of treatment.',\n",
              " 'Thrombopenia < 100 000/ml',\n",
              " 'Total bilirubin < 3.0 mg/dL',\n",
              " 'Total bilirubin within normal institutional limits.',\n",
              " 'Total bilirubin within normal limits and AST/ALT less than 3 times the upper limit of normal (less than 5 times the upper limit of normal in the presence of liver metastases).',\n",
              " 'Total lymphocyte count >= 1000 cells/mm3',\n",
              " 'Transaminases (AST and ALT) <3 X ULN.',\n",
              " 'Treatment exclusion criteria (obtained after anesthesia induction and before chest incision prior to the start of study drug) include: mean pulmonary artery pressure consistently < or equal to 15mmHg',\n",
              " 'Treatment with thrombolysis followed by PCI with stent implantation.',\n",
              " 'Triglyceride concentration of less than 350 mg/dL (less than 3.99 mmol/L) based on blood specimens taken at Visit 1',\n",
              " 'triglycerides <= 4.00 mmol/L drawn  and liver transaminases (ALT  AST) <=50% above the upper limit of normal at Visit 2  with no active liver disease  and/or creatine kinase (CK) <=50% above the upper limit of normal',\n",
              " 'Uncontrolled diabetes mellitus (HbA1c >11% within the last 1 month prior to Screening)',\n",
              " 'Uncontrolled hypertension (diastolic BP > 100 mm Hg or systolic BP > 200 mm Hg)',\n",
              " 'Untreated  current  and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory',\n",
              " 'WBC > 15 000/mm3 within 72 hours of surgery',\n",
              " 'WBC > 4 000/ml  ANC > 1 500/ml  platelets>100 000/ml',\n",
              " 'Weight greater than 100kg.',\n",
              " 'White cell counts >= 4 000 cells/mm3',\n",
              " 'WHO diagnostic criteria for diabetes mellitus is fasting plasma glucose > 7.0 mmol/l (126 mg/dl) or 2-h plasma glucose > 11.1 mmol/l (200mg/dl).',\n",
              " 'with Karnofsky Score > 70',\n",
              " 'You must have stable glycemic control.',\n",
              " 'Zubrod performance status of 0 - 2',\n",
              " 'Zubrod performance status of 0-1.',\n",
              " 'Good physical health on the basis of medical history  physical examination  and laboratory screening.',\n",
              " 'Inclusion Criteria: Presence on a tissue biopsy of large non septated hyphae compatible with zygomycete',\n",
              " ...]"
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def TransformToVector(inputStr):\n",
        "    attList=inputStr.split(\",\")\n",
        "    return [attList[0]] # spam label, list of sentence as attributes\n",
        "\n",
        "patientXformed=patientData.map(TransformToVector)\n",
        "\n",
        "patientDf= SpSession.createDataFrame(patientXformed, [\"patient_characteristics\"])\n",
        "patientDf.cache()\n",
        "patientDf.select(\"patient_characteristics\").show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ntIvpG6z9CB-",
        "outputId": "3b9a849f-dea5-4329-dae4-6506f75a5282"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "+-----------------------+\n",
            "|patient_characteristics|\n",
            "+-----------------------+\n",
            "|   Excluded: Patient...|\n",
            "|   Current substance...|\n",
            "|   Subjects who cons...|\n",
            "|   Excessive consump...|\n",
            "|   History of drug a...|\n",
            "|           Non-smokers.|\n",
            "|   Smokers may parti...|\n",
            "|   Regular use of al...|\n",
            "|   Use of soft drugs...|\n",
            "|   Subject has been ...|\n",
            "|   subjects who have...|\n",
            "|   Current use of to...|\n",
            "|   Exclusion Criteri...|\n",
            "|   alcoholism  drug ...|\n",
            "|   Be current smoker...|\n",
            "|   History of signif...|\n",
            "|   History of signif...|\n",
            "|             Inebriated|\n",
            "|          or abstinence|\n",
            "|   Patients who are ...|\n",
            "+-----------------------+\n",
            "only showing top 20 rows\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "(trainingData, testData) = patientDf.randomSplit([0.9, 0.1])\n",
        "trainingData.count()\n",
        "testData.count()\n",
        "testData.collect()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KI0dAHkU9zcC",
        "outputId": "9cef6adf-ebb2-4e03-dc56-cb2abfe7d82e"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Row(patient_characteristics='(Note: Prior history of deep vein thrombosis will not exclude subjects from participating in this study.)'),\n",
              " Row(patient_characteristics=\"(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept 'blinded' until data analysis)\"),\n",
              " Row(patient_characteristics='(Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.)'),\n",
              " Row(patient_characteristics='18 years of age and older'),\n",
              " Row(patient_characteristics='2 positive Hepatitis B surface antigen results 6 months apart'),\n",
              " Row(patient_characteristics='20 000/mL'),\n",
              " Row(patient_characteristics='50 copies/ml for the last 6 months on HAART therapy.'),\n",
              " Row(patient_characteristics='8.0 g/dL'),\n",
              " Row(patient_characteristics='A CD4+ count between 200 and 500 cells/mm3.'),\n",
              " Row(patient_characteristics='A current diagnosis of severe and unstable cardiovascular disease.'),\n",
              " Row(patient_characteristics='A disability that may prevent the subject from completing all study requirements  .  blindness  deafness  severe language difficulty).'),\n",
              " Row(patient_characteristics='A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to Exelon or to other cholinergic compounds  .  pilocarpine  bethanechol  tacrine  velnacrine  donepezil  metrifonate  or physostigmine)'),\n",
              " Row(patient_characteristics='AST and ALT levels which are less than or equal to 10 times the upper limit of normal.'),\n",
              " Row(patient_characteristics='Abuse alcohol or require drugs which  in the opinion of the investigator  may increase the risk of pancreatitis.'),\n",
              " Row(patient_characteristics='Accepts Healthy Volunteers: Diagnosis of von Hippel-Lindau syndrome (VHL) by the Urologic Oncology Branch using germ line analysis OR clinical criteria and family history'),\n",
              " Row(patient_characteristics='Active malignancy of cervix  uterus  fallopian tube(s) or ovary > Stage I  or bladder of any Stage'),\n",
              " Row(patient_characteristics='Advanced (Stage III or IV)  histologically-documented epithelial ovarian cancer or primary peritoneal cancer (excluding small  round-cell histologies).'),\n",
              " Row(patient_characteristics='Age limits (see below)'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 10 Years and older'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 13 Years and older'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 18 Years to 26 Years'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 18 Years to 55 Years'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 18 Years to 75 Years'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 18 Years to 95 Years'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 20 Years to 64 Years'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 21 Years to 50 Years'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: 30 Years and older'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: up to 3 Months'),\n",
              " Row(patient_characteristics='Ages Eligible for Study: up to 3 Years'),\n",
              " Row(patient_characteristics='Allergy to trial required medications'),\n",
              " Row(patient_characteristics='Anamnestic or clinical signs of disease in lungs  liver endocrine organs or brain or neoplastic disease'),\n",
              " Row(patient_characteristics='Angina pectoris requiring anti-anginal treatment'),\n",
              " Row(patient_characteristics='Antiretrovirals.'),\n",
              " Row(patient_characteristics='Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  immunologic  psychiatric  or metabolic disease'),\n",
              " Row(patient_characteristics='Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  psychiatric  or metabolic disease.'),\n",
              " Row(patient_characteristics='Any condition or disease that may interfere with the evaluation of at least 2 lumbar vertebrae (not necessarily contiguous)  determined in a screening radiograph by a radiologist at the central facility (eg  confluent aortic calcifications  severe osteoar'),\n",
              " Row(patient_characteristics=\"Any food allergy  intolerance  restriction or special diet that  in the opinion of the Medical Sub- Investigator  could contraindicate the subject's participation in this study.\"),\n",
              " Row(patient_characteristics='Any medical condition that may be exacerbated by bleeding  including a known bleeding disorder such as a coagulation defect  thrombocytopenia  active gastric or duodenal ulcer  or history of GI bleeding.'),\n",
              " Row(patient_characteristics='Any other solid lesion(s) of the pancreas'),\n",
              " Row(patient_characteristics='Any unstable cardio-vascular disease   unstable hypertensive disease needing modification or introduction of an anti-hypertensive treatment)'),\n",
              " Row(patient_characteristics='Are (1)NYHA Class IV or (2)NYHA Class III with highest calculated CrCl  60mL/min within the previous 30 days'),\n",
              " Row(patient_characteristics='Are allergic to study drugs or any ingredient in them.'),\n",
              " Row(patient_characteristics='Are unable to take medications by mouth.'),\n",
              " Row(patient_characteristics='Asymptomatic aneurysm'),\n",
              " Row(patient_characteristics='At least one bidimensionally measurable lesion with clearly defined margins documented by: medical photograph for skin and oral lesions  plain X-ray with at least one diameter 0.5 cm or greater  CT  MRI  or palpation with both diameters 2 cm or greater'),\n",
              " Row(patient_characteristics='Atrial fibrillation/flutter'),\n",
              " Row(patient_characteristics='Available to participate in follow-up for the duration of study (14 months)'),\n",
              " Row(patient_characteristics='Be at least 18 years of age'),\n",
              " Row(patient_characteristics='Be current smokers of cigarettes (past 7 days)'),\n",
              " Row(patient_characteristics='CKD stage 3 (GFR 30 - 59 ml/min) for CKD group'),\n",
              " Row(patient_characteristics='CMV prophylaxis.'),\n",
              " Row(patient_characteristics='Cardiac disease'),\n",
              " Row(patient_characteristics='Chronic medical  congenital  or developmental disorder that  in the opinion of the investigator  could interfere with trial conduct or completion.'),\n",
              " Row(patient_characteristics='Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.'),\n",
              " Row(patient_characteristics='Clinically significant illnesses within 4 weeks of the administration of study medication'),\n",
              " Row(patient_characteristics='Clinically significant illnesses within 4 weeks of the administration of study medication'),\n",
              " Row(patient_characteristics='Clinically significant oral lesions or dental conditions that would have interfered with eating a regular diet'),\n",
              " Row(patient_characteristics='Clinically significant pulmonary or neurologic impairment  such as intubation or coma'),\n",
              " Row(patient_characteristics='Concomitant conditions  diseases  medications and/or clinical history'),\n",
              " Row(patient_characteristics='Conditions listed in Exclusion Co-Existing Conditions and symptoms.'),\n",
              " Row(patient_characteristics='Confirmed written informed consent'),\n",
              " Row(patient_characteristics='Consent of patient and parent or guardian if less than 18 years of age.'),\n",
              " Row(patient_characteristics='Corrected QT interval < 0.47 seconds'),\n",
              " Row(patient_characteristics='Current clinically significant suicidal ideation'),\n",
              " Row(patient_characteristics='Current history of uncontrolled hypertension  insulin dependent or uncontrolled diabetes  cardiovascular disease unless controlled and stable for 6 months or more  bleeding disorders  or autoimmune disorders such as fibromyalgia  chronic fatigue syndrome '),\n",
              " Row(patient_characteristics='Developmental delay  neurologic disorder  or seizure disorder.'),\n",
              " Row(patient_characteristics='Diaphragmatic weakness such that patients are unable to tolerate supine position  or swallowing impairment such that patients are unable to maintain nutrition without use of gastrostomy.'),\n",
              " Row(patient_characteristics='Evidence of nasal or pharyngeal obstruction on physical examination.'),\n",
              " Row(patient_characteristics='Exclude if T3 uptake is less than 19%'),\n",
              " Row(patient_characteristics='Excluded: (within 30 days prior to study entry)'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Abnormal EKG'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Clinically significant abnormalities found during medical screening'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Cognitively impaired'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Have a diagnosis of learning disability or organic brain syndrome.'),\n",
              " Row(patient_characteristics='Exclusion Criteria: History or presence of significant cardiovascular  pulmonary  hepatic  renal  hematologic  gastrointestinal  endocrine  immunologic  dermatologic  neurologic or psychiatric disease'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Hypersensitivity to the active ingredient or one of the components of the drug'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Not cases of Kawasaki disease'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Other kidney disease'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Patient less than 18 years of age'),\n",
              " Row(patient_characteristics=\"Exclusion Criteria: Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study\"),\n",
              " Row(patient_characteristics='Exclusion Criteria: Planned aortic valve replacement or repair'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Psychiatric conditions other than depression'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Respiratory disease other tha asthma'),\n",
              " Row(patient_characteristics='Exclusion Criteria: absence of polycystic ovarian syndrome  hydrosalpinx or endometriosis.'),\n",
              " Row(patient_characteristics='Exclusion Criteria: lesion in saphenous vein graft'),\n",
              " Row(patient_characteristics='Exclusion: Have onset of migraine after age 50'),\n",
              " Row(patient_characteristics='Fasting triglyceride levels of >= 400 mg/dL (4.5 mmol/L)'),\n",
              " Row(patient_characteristics='Fit one of the zidovudine use groups listed in Disease Status'),\n",
              " Row(patient_characteristics='Frequent vomiting or medical condition that could interfere with oral medication intake  '),\n",
              " Row(patient_characteristics='Full passive ROM at the wrist and the thumb  index and long finger MCP joints on the affected side'),\n",
              " Row(patient_characteristics='GI symptoms for at least 2 months before entering study'),\n",
              " Row(patient_characteristics='Glaucoma'),\n",
              " Row(patient_characteristics='Glaucoma'),\n",
              " Row(patient_characteristics='Granulocytes >= 1 500/ul  Platelets >= 100 000/ul  Creatinine >=ULN  Bilirubin >=1.5 mg/dl  AST >=2.5 x ULN'),\n",
              " Row(patient_characteristics='HIV exposure'),\n",
              " Row(patient_characteristics='HIV seropositive.'),\n",
              " Row(patient_characteristics='Have a CD4+ count of 50 cells/mm3 or more.'),\n",
              " Row(patient_characteristics='Have a history of drug abuse in the past 2 years and/or positive finding on urinary drug screening  other than prescribed medication.'),\n",
              " Row(patient_characteristics=\"Have an active  ongoing gastrointestinal disease or infection such as colitis  diverticulitis  Crohn's disease  peptic ulcer disease  giardiasis  or cryptosporidiosis.\"),\n",
              " Row(patient_characteristics='Have an active implantable device'),\n",
              " Row(patient_characteristics='Have cardiac disease including congestive heart failure or arrhythmia'),\n",
              " Row(patient_characteristics='History of HIV infection'),\n",
              " Row(patient_characteristics='History of allergic reactions or anaphylaxis to immunizations or to any vaccine component'),\n",
              " Row(patient_characteristics='History of angioedema  hereditary or idiopathic'),\n",
              " Row(patient_characteristics='History of grade 2 or higher peripheral neuropathy.'),\n",
              " Row(patient_characteristics='History of previous closed head trauma or brain injury'),\n",
              " Row(patient_characteristics='History of smoking  alcoholism  and use of illicit drugs'),\n",
              " Row(patient_characteristics='Hypersensitivity to didanosine (ddI).'),\n",
              " Row(patient_characteristics='If abnormal laboratory results such as : Hb<8 g/dl'),\n",
              " Row(patient_characteristics='If predilation of the lesion is visually deemed necessary it should be performed prior to measuring the length of the lesion.'),\n",
              " Row(patient_characteristics='If they are unable to provide informed consent because of cognitive deficits'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Age 40 to 80 years  inclusive.'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Are HIV-positive.'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Clinical diagnosis of ALS'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Coronary disease'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Free of active ocular or systemic disease'),\n",
              " Row(patient_characteristics='Inclusion Criteria: HBV DNA positive with DNA levels at screening greater than or equal to 3 000 000 copies/mL.'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Men and women >= 18 years of age'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Presence on a tissue biopsy of large non septated hyphae compatible with zygomycete'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Soft tissue sarcoma chemosensible  stage IV'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Type 2 diabetes'),\n",
              " Row(patient_characteristics='Inclusion Criteria: aged 65 years or older'),\n",
              " Row(patient_characteristics='Inclusion Criteria: biopsied-proved crescentic glomerulonephritis  with rapidly progressive renal failure'),\n",
              " Row(patient_characteristics=\"Inclusion Criteria: confirmed diagnosis of schizophrenia according to DSM-IV-IV from patient's medical files\"),\n",
              " Row(patient_characteristics='Inclusion Criteria: documented dry eye history'),\n",
              " Row(patient_characteristics='Inclusion Criteria: multiple trauma injury  injury severity score (ISS) > 18 with'),\n",
              " Row(patient_characteristics='Inclusion Criteria: patients aged 75 years old or more'),\n",
              " Row(patient_characteristics='Intestinal obstruction /because of the castor oil content of the drug/'),\n",
              " Row(patient_characteristics='Known HIV  Hepatitis B  or Hepatitis C infection.'),\n",
              " Row(patient_characteristics='Known bleeding disorder.'),\n",
              " Row(patient_characteristics='Known history of corneal disease'),\n",
              " Row(patient_characteristics='Known history of sensitivity to cyclogyl and/or proparacaine HCL 0.5%'),\n",
              " Row(patient_characteristics='Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).'),\n",
              " Row(patient_characteristics='Lack of access to regular meals'),\n",
              " Row(patient_characteristics='Large (>=  3 cm) breast cancer'),\n",
              " Row(patient_characteristics='Live within 10 miles of UCLA'),\n",
              " Row(patient_characteristics='Massive stroke (> 2/3 MCA territory) or any amount of midline shift due to cerebral edema on head CT.'),\n",
              " Row(patient_characteristics='More than 12 weeks (was 24 weeks  AMENDED 3/31/96) of total prior AZT ( > 500 mg/day without serious adverse event)'),\n",
              " Row(patient_characteristics='Must be able to adhere to the study visit schedule and other protocol requirements'),\n",
              " Row(patient_characteristics='Mycotic aneurysm  infectious false aneurysms'),\n",
              " Row(patient_characteristics='Myocardial infarction within 90 days of study start  unstable angina within 14 days of study start  or any clinical evidence of active myocardial ischemia'),\n",
              " Row(patient_characteristics='No active or recent (within the past 30 days) fungal infection'),\n",
              " Row(patient_characteristics='No concurrent combination antiretroviral therapy for HIV-positive patients'),\n",
              " Row(patient_characteristics='No prior end-organ CMV disease - PER AMENDMENT 4/25/96: No prior end organ CMV disease within the past 6 months'),\n",
              " Row(patient_characteristics='Not balanced diabetes'),\n",
              " Row(patient_characteristics='Not classified as morbidly obese (body fat greater than 30% for men and 35% for women)'),\n",
              " Row(patient_characteristics='Other severe chronic diseases  .  cardiologic  renal  or hepatic diseases'),\n",
              " Row(patient_characteristics='Other system illnesses such as renal  hepatic  gastrointestinal  severe hyperlipidemia and hypertension that require medication'),\n",
              " Row(patient_characteristics='Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.'),\n",
              " Row(patient_characteristics='Patient has severe chronic diarrhea  chronic constipation [unless attributed to drugs that will be washed out]  uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.'),\n",
              " Row(patient_characteristics='Patient must have a diagnosis of SLE > 6 months according to the 1989 revised ACR criteria'),\n",
              " Row(patient_characteristics='Patients having any arthrogram of the signal joint within the past 3 months prior to Screening.'),\n",
              " Row(patient_characteristics='Patients may be HBeAg positive  and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive.'),\n",
              " Row(patient_characteristics='Patients must have ECOG performance status 0-2.'),\n",
              " Row(patient_characteristics='Patients who are able to give informed consent'),\n",
              " Row(patient_characteristics='Patients who are not clinically stable such as those who had cardiac arrest  who are intubated  who have active psychosis  or who are cognitively impaired.'),\n",
              " Row(patient_characteristics='Patients who in the judgment of the clinician are likely to violate the protocol regulations or unlikely to complete the study for any reason.'),\n",
              " Row(patient_characteristics='Patients will be eligible for enrollment if they fulfill the following criteria: Histological diagnosis of surgically resected Stage IIB  IIC  Stage III or Stage IV (AJCC criteria) melanoma independent of NY-ESO-1 expression in a tumor biopsy'),\n",
              " Row(patient_characteristics='Patients will be excluded from the study if they fulfill any of the following criteria: Serious illnesses  e.g.  serious infections requiring antibiotics.'),\n",
              " Row(patient_characteristics='Patients with acute Intracerebral hemorrhage diagnosed by neuroimaging'),\n",
              " Row(patient_characteristics='Patients with known history of inflammatory skin disorders  . psoriasis  lupus) that may be exacerbated by Resiquimod.'),\n",
              " Row(patient_characteristics='Patients with medical condition which need urgent or special antihypertentive therapy  such as hypertensive encephalopathy  aortic dissection  acute renal failure  acute pulmonary edema  or acute myocardial infarction'),\n",
              " Row(patient_characteristics='Patients with the following are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.'),\n",
              " Row(patient_characteristics='Performance status of 0-1'),\n",
              " Row(patient_characteristics='Platelet count  >= 100 000/ul'),\n",
              " Row(patient_characteristics='Preexisting peripheral neuropathy must be equal to or less than grade 1'),\n",
              " Row(patient_characteristics='Presence of hypoalbuminaemia < 35 g/L'),\n",
              " Row(patient_characteristics='Presence of serious acute infection requiring parenteral treatment at time of study entry.'),\n",
              " Row(patient_characteristics='Previous enrollment in LABS-1'),\n",
              " Row(patient_characteristics='Provide informed consent'),\n",
              " Row(patient_characteristics='Recent history of drug and/or alcohol abuse'),\n",
              " Row(patient_characteristics='Reference vessel diameter >=  2.5 and >= 3.75 mm by visual estimate'),\n",
              " Row(patient_characteristics='Satisfactory medical assessment with no clinically significant or relevant'),\n",
              " Row(patient_characteristics='Self-reported level of motivation to stop smoking >=  7  on a scale of 1-to-10'),\n",
              " Row(patient_characteristics='Serum bilirubin < 1.5 times ULN'),\n",
              " Row(patient_characteristics='Serum creatinine greater then 2 mg/dl.'),\n",
              " Row(patient_characteristics='Shortening fraction >=  25% by ECHO OR ejection fraction > 30% by MUGA'),\n",
              " Row(patient_characteristics='Signed written informed consent'),\n",
              " Row(patient_characteristics='Significant diarrhea'),\n",
              " Row(patient_characteristics='Significant regional wall motion abnormality on echocardiography at the time of acute PCI (ejection fraction >= 50% on visual estimation).'),\n",
              " Row(patient_characteristics='Subject has multiple and/or severe allergies to drugs or food'),\n",
              " Row(patient_characteristics='Subject may be of any age'),\n",
              " Row(patient_characteristics='Subject must have an undetectable viral load (VL) &lt'),\n",
              " Row(patient_characteristics='Subjects must have triglyceride concentrations of < 3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).'),\n",
              " Row(patient_characteristics='Subjects who consume >14 alcoholic drinks per week.'),\n",
              " Row(patient_characteristics='Subjects who have a history of alcohol or drug abuse within 1 year of study entry'),\n",
              " Row(patient_characteristics='Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.'),\n",
              " Row(patient_characteristics='Systolic blood pressure (SBP) consistently < 90 mm Hg'),\n",
              " Row(patient_characteristics='Target lesion stenosis is >= 50% and <100% (minimum TIMI flow I at the time of the PCI procedure) (visual estimate)'),\n",
              " Row(patient_characteristics='The coronary artery lesion should be >=27 mm in length (a margin of 3mm proximal and 3mm distal is recommended) and should be entirely covered by one single Genous Bio-engineered R stentTM'),\n",
              " Row(patient_characteristics='The presence of alcoholism or drug abuse within the past year'),\n",
              " Row(patient_characteristics='Total bilirubin < 3.0 mg/dL'),\n",
              " Row(patient_characteristics='Total bilirubin within normal institutional limits.'),\n",
              " Row(patient_characteristics='Treatment with thrombolysis followed by PCI with stent implantation.'),\n",
              " Row(patient_characteristics='Unable to obtain or refusal to consent prior to surgery'),\n",
              " Row(patient_characteristics='Uncontrolled diabetes mellitus (HbA1c >11% within the last 1 month prior to Screening)'),\n",
              " Row(patient_characteristics='Untreated  current  and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory'),\n",
              " Row(patient_characteristics='Weighing at least 60 kg  who are within 10% of their ideal weights '),\n",
              " Row(patient_characteristics=\"Within these three months of treatment  the subject's cognitive condition must be clinically unchanged or worse for the subject to be acceptable\"),\n",
              " Row(patient_characteristics='[Note: If one of the two values is < 400 the patient will be excluded'),\n",
              " Row(patient_characteristics='age 18-65 years'),\n",
              " Row(patient_characteristics='and/or documented history of unstable angina or non-Q wave myocardial infarction.'),\n",
              " Row(patient_characteristics='bifurcation lesions (side branch > 2 0 mm)'),\n",
              " Row(patient_characteristics='bmi (body mass index) 19-30 kg / m2 (42-66 lb / m2) '),\n",
              " Row(patient_characteristics='chronic total occlusion'),\n",
              " Row(patient_characteristics='cognitive deficits'),\n",
              " Row(patient_characteristics='combination of points 1 - 4'),\n",
              " Row(patient_characteristics='documented history of atherothrombotic cerebrovascular disease'),\n",
              " Row(patient_characteristics='falciparum of between 250 and 100 000 asexual parasites/mm3 as determined by microscopic exam of the thick or thin smear'),\n",
              " Row(patient_characteristics='fasting blood sugar greater than 110 mg/dl'),\n",
              " Row(patient_characteristics='have a body mass index (bmi) >= 18 kg / m2 '),\n",
              " Row(patient_characteristics='have height or weight < the 5 th percentile. '),\n",
              " Row(patient_characteristics='informed consent signed'),\n",
              " Row(patient_characteristics='left main stenosis'),\n",
              " Row(patient_characteristics='lesion must be covered by stent length of no more than 24 mm and stent diameter of no more than 3 5 mm'),\n",
              " Row(patient_characteristics='leukopenia and/or thrombocytopenia'),\n",
              " Row(patient_characteristics='normal weight-for-height weight 50-80 kg '),\n",
              " Row(patient_characteristics='or if serum creatinine > upper limit of normal  a calculated creatinine clearance < 60 mL/min/1.73 m2).'),\n",
              " Row(patient_characteristics='study participants had to have a normal Pap smear within the previous 12 months'),\n",
              " Row(patient_characteristics='(3) an aneurysm clip in their brain'),\n",
              " Row(patient_characteristics='--Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates  carbamazepine  phenytoin glucocorticoids  omerprazole'),\n",
              " Row(patient_characteristics=\"Ability to visit the doctor's office for scheduled visits\"),\n",
              " Row(patient_characteristics='Able to walk without assistive devices'),\n",
              " Row(patient_characteristics='Accepts Healthy Volunteers  '),\n",
              " Row(patient_characteristics='Accepts Healthy Volunteers: Inclusion:'),\n",
              " Row(patient_characteristics='Adequate hepatic function'),\n",
              " Row(patient_characteristics='Adequate pulmonary function'),\n",
              " Row(patient_characteristics='African American'),\n",
              " Row(patient_characteristics='African American or Latino'),\n",
              " Row(patient_characteristics='African-Americans.'),\n",
              " Row(patient_characteristics='Allowed: Atovaquone  IV pentamidine  trimethoprim-dapsone  clindamycin-primaquine  trimetrexate  or TMP/SMX for acute PCP.'),\n",
              " Row(patient_characteristics='Allowed: Blood transfusions for hematologic toxicity.'),\n",
              " Row(patient_characteristics='Alternative medications including megadose vitamins  herbal preparations  tonics  extracts  etc'),\n",
              " Row(patient_characteristics='Any history of lymphoproliferative disorder.'),\n",
              " Row(patient_characteristics='Any other clinical condition or prior therapy that  in the opinion of the clinic physician  would make the subject unsuitable for the study or unable to comply with the dosing requirements'),\n",
              " Row(patient_characteristics='Are pregnant  nursing  or planning pregnancy prior to study enrollment'),\n",
              " Row(patient_characteristics='Are receiving or plan to receive chemotherapy for cancer.'),\n",
              " Row(patient_characteristics='At least 21 days since prior radiotherapy and recovered'),\n",
              " Row(patient_characteristics='Be likely to comply with the study protocol'),\n",
              " Row(patient_characteristics='Biologic response modifiers such as interferon and IL-2.'),\n",
              " Row(patient_characteristics='Candidate for curative treatment such as prostatectomy or radiotherapy'),\n",
              " Row(patient_characteristics='Carafate.'),\n",
              " Row(patient_characteristics='Chinese speaking  capable to understand the study'),\n",
              " Row(patient_characteristics='Clarithromycin.'),\n",
              " Row(patient_characteristics='Clofazimine.'),\n",
              " Row(patient_characteristics='Concomitant use of felbamate or use of felbamate within 2 months prior to Visit 1.'),\n",
              " Row(patient_characteristics='Concurrent Treatment: Excluded:'),\n",
              " Row(patient_characteristics='Concurrent neoplasms not specifically allowed.'),\n",
              " Row(patient_characteristics='Contraindication to ??-adrenoceptor antagonist therapy or brimonidine therapy'),\n",
              " Row(patient_characteristics='Corticosteroids.'),\n",
              " Row(patient_characteristics='Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)'),\n",
              " Row(patient_characteristics='Currently taking psychostimulant medication'),\n",
              " Row(patient_characteristics='Donor: Partially HLA matched family donor'),\n",
              " Row(patient_characteristics='ECT treatment within the past two months'),\n",
              " Row(patient_characteristics='ER  PgR and HER-2 status not determined.'),\n",
              " Row(patient_characteristics='ER &/or PR positive'),\n",
              " Row(patient_characteristics='Enrolled in other studies at the same time'),\n",
              " Row(patient_characteristics='Enrollment in other trials designed to modify post-procedure behaviors.'),\n",
              " Row(patient_characteristics='Erythropoietin.'),\n",
              " Row(patient_characteristics='Excluded within 30 days of study entry: Antiretroviral agents other than zidovudine (AZT).'),\n",
              " Row(patient_characteristics='Excluded: Immunomodulators  biologic response modifiers  interferon  or investigational agents that may influence course of CMV infection.'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Breast feeding female subjects'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Multiple birth greater than twins'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Presence of ventriculoperitoneal shunt'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Will not be eligible if not a part of the previous study'),\n",
              " Row(patient_characteristics='Exclusion Criteria: Workers absent from the workplace during all the study period.'),\n",
              " Row(patient_characteristics='Exclusion Criteria: clinical evidence of metastatic disease'),\n",
              " Row(patient_characteristics='Exclusion Criteria: inability to read or understand English'),\n",
              " Row(patient_characteristics='Exposure to another investigational drug within 14 days prior to start of study treatment.'),\n",
              " Row(patient_characteristics='Female patients of child bearing age who have a positive pregnancy test on admission.'),\n",
              " Row(patient_characteristics='Females should be either of nonchildbearing potential as a result of surgery or menopause (1 year after onset)  or of childbearing potential and practicing a medically acceptable method of contraception  .  abstinence  a barrier method plus spermicide  or'),\n",
              " Row(patient_characteristics='For all subjects female gender'),\n",
              " Row(patient_characteristics='HIV protease inhibitors'),\n",
              " Row(patient_characteristics='Had Pap smear evidence of atypical squamous cells or adenocarcinoma or other malignancy'),\n",
              " Row(patient_characteristics='Has cardiac pacemaker or other electromedical implant'),\n",
              " Row(patient_characteristics='Have changes in diet or physical activity that might explain changes in body fat.'),\n",
              " Row(patient_characteristics='Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs).'),\n",
              " Row(patient_characteristics='Have had systemic treatment for cancer within 30 days of entering the study.'),\n",
              " Row(patient_characteristics='Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other study.'),\n",
              " Row(patient_characteristics='Have used any investigational drug within the previous 1 month or 5 half-lives of the investigational agent  whichever is longer  or 3 months for any biologic of unknown half-life'),\n",
              " Row(patient_characteristics='Have used any topical cosmetics or medicated products on the affected nails within 2 weeks of baseline visit'),\n",
              " Row(patient_characteristics='Having received any approved or investigational antiretroviral  immunosuppressive  or cytotoxic drugs or any other experimental drug with 4 weeks of study entry.'),\n",
              " Row(patient_characteristics='Hormone receptor status: ER status known'),\n",
              " Row(patient_characteristics='Hormone resistant disease required of receptor positive patients'),\n",
              " Row(patient_characteristics='If in the opinion of the treating physician  sufficient time has elapsed  such that it is extremely likely that the patient has been cured of a prior malignancy  the patient may be eligible for the protocol.'),\n",
              " Row(patient_characteristics='If patients are not taking any analgesic/anti-inflammatory medication or have not taken any pain medication (prescription [Rx] or over-the-counter [OTC]) in the previous 3 days from Screening then they should have a VAS pain score after walking on a 50 ft'),\n",
              " Row(patient_characteristics='If they refuse to participate.'),\n",
              " Row(patient_characteristics='In VGPR or PR after salvage therapy'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Consecutive patients undergoing percutaneous coronary intervention at an enrolling center by study investigators'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Female'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Histologically-confirmed diagnosis of breast (females only) or prostate cancer'),\n",
              " Row(patient_characteristics='Inclusion Criteria: Patients must have histologically confirmed thyroid cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.'),\n",
              " Row(patient_characteristics='Intact uterus (womb).'),\n",
              " Row(patient_characteristics='Intraocular surgery in the study eye within 60 days prior enrollement'),\n",
              " Row(patient_characteristics='Itraconazole.'),\n",
              " Row(patient_characteristics='Known central nervous system or brain metastases.'),\n",
              " Row(patient_characteristics='Low carbohydrate diet (less than 150 g/day) for 3 days preceding the OGTT'),\n",
              " Row(patient_characteristics='Lung function normal'),\n",
              " Row(patient_characteristics='Major surgery < 28 days prior to registration.'),\n",
              " Row(patient_characteristics='Major surgery within 4 weeks prior to Day 1.'),\n",
              " Row(patient_characteristics='Major surgery within 8 weeks prior to the Baseline Visit'),\n",
              " Row(patient_characteristics='Males and females'),\n",
              " Row(patient_characteristics='Mechanically-ventilated during the first week of life'),\n",
              " Row(patient_characteristics='Medical conditions for which changes in diet and exercise levels would be contraindicated'),\n",
              " Row(patient_characteristics='Men should exercise appropriate contraceptive measures while participating on the study.'),\n",
              " Row(patient_characteristics='Menopausal status not specified'),\n",
              " Row(patient_characteristics='Military returnees from OIF/OEF'),\n",
              " Row(patient_characteristics='Minorities are actively recruited.'),\n",
              " Row(patient_characteristics='More than 14 days since prior and no concurrent inhibitors or inducers of CYP3A4  including any of the following: Rifapentine'),\n",
              " Row(patient_characteristics='Must have adequate bone marrow  renal and liver function.'),\n",
              " Row(patient_characteristics='Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry'),\n",
              " Row(patient_characteristics='Must live in selected communities in eastern Massachusetts'),\n",
              " Row(patient_characteristics='Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).'),\n",
              " Row(patient_characteristics='NOTE: This protocol is approved for prisoner participation.'),\n",
              " Row(patient_characteristics='Need for psychoactive medications other than the study drugs  except for one benzodiazepine or hypnotic given at a stable dose.'),\n",
              " Row(patient_characteristics='New York Metro Area resident'),\n",
              " Row(patient_characteristics='No prior tubule  DNA  or mitosis-targeting agents for RCC'),\n",
              " Row(patient_characteristics='Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.'),\n",
              " Row(patient_characteristics='Non-epithelial ovarian tumors.'),\n",
              " Row(patient_characteristics='Noncompliance with current medical regimen'),\n",
              " Row(patient_characteristics='Normal thyroid function'),\n",
              " Row(patient_characteristics='Not pregnant  if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.'),\n",
              " Row(patient_characteristics='Outpatient status required'),\n",
              " Row(patient_characteristics='Oxcarbazepine'),\n",
              " Row(patient_characteristics='Participant is likely to comply with the study treatment during the study period'),\n",
              " Row(patient_characteristics='Participation in another clinical study'),\n",
              " Row(patient_characteristics='Participation in other trials'),\n",
              " Row(patient_characteristics='Participation with 30 days in investigational study.'),\n",
              " Row(patient_characteristics='Patient has had a malignancy within the past 2 years other than basal cell carcinoma.'),\n",
              " Row(patient_characteristics='Patient has had neurolytic or neurosurgical treatment for PHN.'),\n",
              " Row(patient_characteristics='Patient life expectancy is less than 12 months'),\n",
              " Row(patient_characteristics='Patient must have a minimum washout period of greater than 5 times the half-life of the drug of any of the following medications: benzodiazepines  skeletal muscle relaxants  orally administered steroids  capsaicin  mexiletene  centrally acting analgesics '),\n",
              " Row(patient_characteristics='Patient treated with azathioprine  methotrexate  or hydrochloroquine must be on a stable dose with no change in dose for at least 6 weeks preceding the study'),\n",
              " Row(patient_characteristics='Patient unable to be regularly followed-up.'),\n",
              " Row(patient_characteristics='Patient undergoing intracranial surgery  carotid endarterectomy  or retinal surgery'),\n",
              " Row(patient_characteristics='Patient using any investigational agents within the longer of 30 days or 10 half-lives of the agent'),\n",
              " Row(patient_characteristics='Patients must also be willing to abstain from any intra-articular (i.a.) or peri-articular injections to the knee or surgery during the course of the trial  except for the assigned study product.'),\n",
              " Row(patient_characteristics='Patients receiving any articular procedures  such as transplants  to the study knee.'),\n",
              " Row(patient_characteristics='Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.'),\n",
              " Row(patient_characteristics='Patients who refused to participate'),\n",
              " Row(patient_characteristics='Patients who take medications on a chronic basis  such as antihypertensive medications or thyroid replacement therapy  etc'),\n",
              " Row(patient_characteristics='Patients with a history of tracheostomy'),\n",
              " Row(patient_characteristics='Patients with any of the following prior conditions are excluded: History of prior saquinavir (SQV) therapy for more than 14 days.'),\n",
              " Row(patient_characteristics='Patients with clinical concern for brain metastases must have a negative brain CT scan or MRI within the past 56 days'),\n",
              " Row(patient_characteristics='Patients with hormone receptor (ER and/or PgR) positive or both unknown.'),\n",
              " Row(patient_characteristics='Patients with the following symptoms or conditions are excluded: Evidence of retinal vascular or related infectious disease or other retinal lesions that would interfere with the ability to detect responses to therapy or progression.'),\n",
              " Row(patient_characteristics='Patients within 6 months of a coronary intervention  including PCI or CABG.'),\n",
              " Row(patient_characteristics='Perceived inability to comply with the study protocol'),\n",
              " Row(patient_characteristics='Positive testing for hepatitis B  hepatitis C or HIV at screening'),\n",
              " Row(patient_characteristics='Pre-existing endocardial pacing leads '),\n",
              " Row(patient_characteristics=\"Prednisone dose in patient's receiving alternate day therapy will be the mean daily prednisone dose\"),\n",
              " Row(patient_characteristics='Pregnant female.'),\n",
              " Row(patient_characteristics='Pregnant or lactating females.'),\n",
              " Row(patient_characteristics='Pregnant or lactating women  as treatment involves unforeseeable risks to the participant and to the embryo or fetus'),\n",
              " Row(patient_characteristics='Pregnant patients'),\n",
              " Row(patient_characteristics='Previous participation in an MPC-7869 clinical study.'),\n",
              " Row(patient_characteristics='Prior biologic or immunotherapy < 14 days prior to registration'),\n",
              " Row(patient_characteristics='Prior irradiation other than basal cell cancer of skin'),\n",
              " Row(patient_characteristics='Radiotherapy for the treatment of a symptomatic  '),\n",
              " Row(patient_characteristics='Recipient of heart transplant'),\n",
              " Row(patient_characteristics='Recommended: Standard immunizations'),\n",
              " Row(patient_characteristics='Self identification of Black  White or Hispanic Ethnicity'),\n",
              " Row(patient_characteristics='Severe arrhythmia'),\n",
              " Row(patient_characteristics='Severe respiratory insufficiency'),\n",
              " Row(patient_characteristics='Sex Male or female'),\n",
              " Row(patient_characteristics='Show evidence of significant  active  hepatic disease'),\n",
              " Row(patient_characteristics='Significant neurologic/psychiatric disorders'),\n",
              " Row(patient_characteristics='Smoker lives in the household'),\n",
              " Row(patient_characteristics='Soft tissue disease within a prior irradiated field must have progressed to be considered assessable'),\n",
              " Row(patient_characteristics='Started antidepressant medication for treatment of depression during past 6 weeks'),\n",
              " Row(patient_characteristics='Subject has a known family history of sudden cardiac death or ventricular arrhythmia'),\n",
              " Row(patient_characteristics='Subject has a recent history of eye infection or other inflammatory eye conditions'),\n",
              " Row(patient_characteristics='Subject has renal insufficiency'),\n",
              " Row(patient_characteristics='Subject is pregnant'),\n",
              " Row(patient_characteristics='Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.'),\n",
              " Row(patient_characteristics='Subjects must be available for follow-up visits to comply with the requirements of the protocol.'),\n",
              " Row(patient_characteristics='Subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.'),\n",
              " Row(patient_characteristics='Subjects must have documented coronary heart disease (CHD)'),\n",
              " Row(patient_characteristics='Subjects of child-bearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment (about 5 half lives).'),\n",
              " Row(patient_characteristics='Subjects who have participated in another clinical trial with 28 days of study start.'),\n",
              " Row(patient_characteristics='Subjects who have taken prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication  except for topical products without systemic absorption'),\n",
              " Row(patient_characteristics='Suspicion of abuse or non-compliance'),\n",
              " Row(patient_characteristics='Symptomatic as evidenced by transient ischemic attack or non-disabling stroke in the hemisphere supplied by the target vessel within 180 days of procedure'),\n",
              " Row(patient_characteristics='Symptomatic congestive heart failure'),\n",
              " Row(patient_characteristics='Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.'),\n",
              " Row(patient_characteristics='The patient must be clinically stable enough for outpatient evaluation.'),\n",
              " Row(patient_characteristics='Treatment with IV tPA or other thrombolytic agent.'),\n",
              " Row(patient_characteristics='Treatment with psychotropic medication in the previous month.'),\n",
              " Row(patient_characteristics='Trimethoprim / sulfamethoxazole (Bactrim).'),\n",
              " Row(patient_characteristics='Troleandomycin'),\n",
              " Row(patient_characteristics='Tumorous disease'),\n",
              " Row(patient_characteristics='Ulcers'),\n",
              " Row(patient_characteristics='Unable to remain in supine position for at least 60 minutes'),\n",
              " Row(patient_characteristics='Uncontrolled systemic illness.'),\n",
              " Row(patient_characteristics='Unknown ER and PR status'),\n",
              " Row(patient_characteristics='Ureteral stent'),\n",
              " Row(patient_characteristics='VA Medical Center or outpatient clinics with at least 3000 patients.'),\n",
              " Row(patient_characteristics='Willing and able to comply with all study requirements'),\n",
              " Row(patient_characteristics='Willing to undergo cranial osteopathic manipulation'),\n",
              " Row(patient_characteristics='Willing to undergo serial non-invasive imaging'),\n",
              " Row(patient_characteristics='Willing to use acceptable methods of contraception'),\n",
              " Row(patient_characteristics='Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy'),\n",
              " Row(patient_characteristics='You cannot be in this study if you any of the following: History of cardiac disease  with New York Heart Association Class II or greater with congestive heart failure'),\n",
              " Row(patient_characteristics='You must be able to swallow the LY317615 tablets'),\n",
              " Row(patient_characteristics='You must have been taking the same dose of amitriptyline once daily at bedtime for at least four (4) weeks.'),\n",
              " Row(patient_characteristics='a drug or treatment known to cause major organ system toxicity during the past four weeks'),\n",
              " Row(patient_characteristics='failure to comply with study CLIC477D2303'),\n",
              " Row(patient_characteristics='for those on Coumadin  INR > 3.0'),\n",
              " Row(patient_characteristics='has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization'),\n",
              " Row(patient_characteristics='hormone receptor status: estrogen receptor positive '),\n",
              " Row(patient_characteristics='intrauterine device (IUD)'),\n",
              " Row(patient_characteristics='intrauterine progesterone contraceptive system'),\n",
              " Row(patient_characteristics='is pregnant or breast-feeding.'),\n",
              " Row(patient_characteristics='male or female  in- or outpatients'),\n",
              " Row(patient_characteristics='male sex'),\n",
              " Row(patient_characteristics='must be fluent in either English or Chinese (Mandarin or Cantonese)'),\n",
              " Row(patient_characteristics='no concurrent regular exercise of 3 or more hours a week '),\n",
              " Row(patient_characteristics='normal physical activity'),\n",
              " Row(patient_characteristics='patients with ray-treatment or chemotherapy within the last three months'),\n",
              " Row(patient_characteristics='plan to live in the area for 6 months  and'),\n",
              " Row(patient_characteristics='poorly controlled diabetes (HbA1c > 7.0)'),\n",
              " Row(patient_characteristics='previous history of invasive malignancy within the last 5 years  other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix  adequately cone biopsied'),\n",
              " Row(patient_characteristics='previous hormonal therapy as adjuvant treatment for breast cancer'),\n",
              " Row(patient_characteristics='regular exercise ( participating in 2 or more structured exercise sessions weekly for more than or equal to 6 months prior to enrolment).'),\n",
              " Row(patient_characteristics='regularly eats 3 meals/day'),\n",
              " Row(patient_characteristics='severe illnesses  judged by a geriatrician'),\n",
              " Row(patient_characteristics='severe malnutrition)'),\n",
              " Row(patient_characteristics='stenoses of bypass grafts'),\n",
              " Row(patient_characteristics='with contradiction of cardiac and pulmonary diseases'),\n",
              " Row(patient_characteristics='with other organ metastasis or peritoneum metastasis')]"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from pyspark.ml import Pipeline\n",
        "from pyspark.ml.feature import HashingTF, Tokenizer\n",
        "from pyspark.ml.feature import IDF\n",
        "from pyspark.ml.clustering import KMeans"
      ],
      "metadata": {
        "id": "AubLbe6e99FX"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#break sentences into words\n",
        "tokenizer = Tokenizer(inputCol=\"patient_characteristics\", outputCol=\"words\")"
      ],
      "metadata": {
        "id": "HwQ6Nmcn9-Cf"
      },
      "execution_count": 9,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#calculate term frequency (TF)\n",
        "hashingTF = HashingTF(inputCol=tokenizer.getOutputCol(),  outputCol=\"tempfeatures\")"
      ],
      "metadata": {
        "id": "L34fyBYo-CZO"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#calculate TF-IDF\n",
        "tfIdf=IDF(inputCol=hashingTF.getOutputCol(), outputCol=\"features\")"
      ],
      "metadata": {
        "id": "hdDvRgiP-ERW"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kmeans=KMeans(k=10,seed=1)"
      ],
      "metadata": {
        "id": "SLwCuU05-M8G"
      },
      "execution_count": 12,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#build a pipleline\n",
        "pipeline = Pipeline(stages=[tokenizer, hashingTF, tfIdf, kmeans])"
      ],
      "metadata": {
        "id": "ljWs4afg-GxP"
      },
      "execution_count": 13,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Build a model with a pipeline\n",
        "kMeansPipeLineModel=pipeline.fit(trainingData) #training phase"
      ],
      "metadata": {
        "id": "DQ_8rU-07pF6"
      },
      "execution_count": 14,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Predict on test data\n",
        "prediction=kMeansPipeLineModel.transform(testData) # testing phase"
      ],
      "metadata": {
        "id": "D8ZjoUWR73JA"
      },
      "execution_count": 15,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "prediction.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8PBqBEGB754G",
        "outputId": "46b67f6f-d376-4292-eafc-b59ad7182bab"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "+-----------------------+--------------------+--------------------+--------------------+----------+\n",
            "|patient_characteristics|               words|        tempfeatures|            features|prediction|\n",
            "+-----------------------+--------------------+--------------------+--------------------+----------+\n",
            "|   (Note: Prior hist...|[(note:, prior, h...|(262144,[73409,87...|(262144,[73409,87...|         0|\n",
            "|   (The lipid profil...|[(the, lipid, pro...|(262144,[3748,385...|(262144,[3748,385...|         0|\n",
            "|   (Was written - Ga...|[(was, written, -...|(262144,[1546,275...|(262144,[1546,275...|         0|\n",
            "|   18 years of age a...|[18, years, of, a...|(262144,[66776,76...|(262144,[66776,76...|         0|\n",
            "|   2 positive Hepati...|[2, positive, hep...|(262144,[1546,366...|(262144,[1546,366...|         0|\n",
            "|              20 000/mL|        [20, 000/ml]|(262144,[90804,11...|(262144,[90804,11...|         0|\n",
            "|   50 copies/ml for ...|[50, copies/ml, f...|(262144,[1546,305...|(262144,[1546,305...|         0|\n",
            "|               8.0 g/dL|         [8.0, g/dl]|(262144,[2032,114...|(262144,[2032,114...|         0|\n",
            "|   A CD4+ count betw...|[a, cd4+, count, ...|(262144,[29440,33...|(262144,[29440,33...|         0|\n",
            "|   A current diagnos...|[a, current, diag...|(262144,[72914,91...|(262144,[72914,91...|         0|\n",
            "|   A disability that...|[a, disability, t...|(262144,[36319,42...|(262144,[36319,42...|         3|\n",
            "|   A known exaggerat...|[a, known, exagge...|(262144,[17754,22...|(262144,[17754,22...|         3|\n",
            "|   AST and ALT level...|[ast, and, alt, l...|(262144,[27576,33...|(262144,[27576,33...|         0|\n",
            "|   Abuse alcohol or ...|[abuse, alcohol, ...|(262144,[33860,44...|(262144,[33860,44...|         3|\n",
            "|   Accepts Healthy V...|[accepts, healthy...|(262144,[12293,12...|(262144,[12293,12...|         0|\n",
            "|   Active malignancy...|[active, malignan...|(262144,[9276,153...|(262144,[9276,153...|         3|\n",
            "|   Advanced (Stage I...|[advanced, (stage...|(262144,[33358,63...|(262144,[33358,63...|         0|\n",
            "|   Age limits (see b...|[age, limits, (se...|(262144,[139373,1...|(262144,[139373,1...|         0|\n",
            "|   Ages Eligible for...|[ages, eligible, ...|(262144,[66776,76...|(262144,[66776,76...|         8|\n",
            "|   Ages Eligible for...|[ages, eligible, ...|(262144,[66776,76...|(262144,[66776,76...|         8|\n",
            "+-----------------------+--------------------+--------------------+--------------------+----------+\n",
            "only showing top 20 rows\n",
            "\n"
          ]
        }
      ]
    }
  ]
}